Stock Name | Peer Group Rank | RS Rating | 1 Month RS | 3 Month RS | Listing Date | Basic Industry | Market Cap(Cr.) | 1 Day Returns(%) | 1 Week Returns(%) | 1 Month Returns(%) | 3 Month Returns(%) | 6 Month Returns(%) | 1 Year Returns(%) | % from 52W High | % from 52W Low | Chart Type | Stock Price(₹) | 200 Days MA | 150 Days MA | 50 Days MA | 20 Days MA | 200 Days EMA | 50 Days EMA | 21 Days EMA | 20 Days EMA | 10 Days EMA | 30 Days Average Rupee Volume(Cr.) | 1 Month High | 3 Month High | Float Shares(Cr.) | Index | 52 Week High | Volume Spike | Gap Up | Dense Volume | Sector | Free Float(%) | Is HVE | HVE Date | Is Positive Volume HVE | Is HVY | HVY Date | Is Positive Volume HVY | Is HVQ | HVQ Date | Is Positive Volume HVQ | Day Range(%) | Is F&O Stock | Circuit Limit | RVOL | Daily Rupee Turnover 20(Cr.) | Daily Rupee Turnover 50(Cr.) | Daily Rupee Turnover 100(Cr.) | Is NR7 | 20 Days MA Volume | 50 Days MA Volume | 200 Days EMA Volume | 50 Days EMA Volume | 20 Days EMA Volume | Trend Reversal | % from 52W High 200 Days EMA Volume | 200 Days EMA RS | 50 Days EMA RS | 20 Days EMA RS | % from 52W High RS | 5 Days MA ADR(%) | 14 Days MA ADR(%) | 20 Days MA ADR(%) | 30 Days MA ADR(%) | % Days in 125: EMA50 today > yesterday | % Days in 125: Today's price > EMA50 | % from ATH | Quarterly Results Date | Gap Up % | MA Uptrend | FVG | Backtesting Closing Data | Highest Close Since Last Quarter | Past Result Dates | Company Name | Returns since Earnings(%) | Max Returns since Earnings(%) | Latest Investor Presentation Link | Horizontal Resistance Line Data | Tight Zone Data | Inside Bar Dates | VCP Drawings Data | Net Profit Latest Quarter | Net Profit Previous Quarter | Net Profit 2 Quarters Back | Net Profit 3 Quarters Back | Net Profit Last Year Quarter | Net Profit 5 Quarters Back | Net Profit 6 Quarters Back | Net Profit 7 Quarters Back | QoQ % Net Profit Latest | YoY % Net Profit Latest | EPS Latest Quarter | EPS Previous Quarter | EPS 2 Quarters Back | EPS 3 Quarters Back | EPS Last Year Quarter | EPS 5 Quarters Back | EPS 6 Quarters Back | EPS 7 Quarters Back | QoQ % EPS Latest | YoY % EPS Latest | EPS Last Year | EPS 2 Years Back | Sales Latest Quarter | Sales Previous Quarter | Sales 2 Quarters Back | Sales 3 Quarters Back | Sales Last Year Quarter | Sales 5 Quarters Back | Sales 6 Quarters Back | Sales 7 Quarters Back | QoQ % Sales Latest | YoY % Sales Latest | Sales Growth 5 Years(%) | OPM Latest Quarter | OPM Previous Quarter | OPM 2 Quarters Back | OPM 3 Quarters Back | OPM Last Year Quarter | OPM 5 Quarters Back | OPM 6 Quarters Back | OPM 7 Quarters Back | QoQ % OPM Latest | YoY % OPM Latest | Latest Quarter | ROE(%) | ROCE(%) | D/E | OPM TTM(%) | P/E | FII % change QoQ | DII % change QoQ | Promoter % change QoQ | PEG | Forward P/E | Historical P/E 5 Years | Company Info | Promotor Holding Latest Quarter(%) | Public Holding Latest Quarter(%) | FII Holding Latest Quarter(%) | DII Holding Latest Quarter(%) | Promotor Holding Previous Quarter(%) | FII Holding Previous Quarter(%) | DII Holding Previous Quarter(%) | Price to Book | Enterprise Value(Cr.) | Enterprise Value/EBITDA | Enterprise Value/Sales |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 91 | 80 | 83 | 06/08/2021 | Medical-Diversified | 184 | -4.5 | -9 | -2.7 | -0.2 | -9.1 | 78.5 | 34.8 | 107.9 | DAILY | 65.18 | 72.02 | 75.14 | 68.54 | 71.37 | 69.95 | 70.6 | 70.07 | 70.06 | 69.35 | 1.7 | False | False | 1.73 | NA | False | False | False | 208.6 | Healthcare | 60.9 | False | False | False | False | False | False | 4.6 | False | 10 | 0.15 | 1.3 | 1.3 | 1 | False | 235739 | 241102.04 | 154147.15 | 222841.54 | 187107.12 | False | 3.5 | 85.02 | 83.85 | 86.08 | 2.2 | 5.1 | 6.3 | 6.3 | 6.3 | 51.2 | 51.2 | 34.8 | 11/02/2026 | -3.8 | True,False;True,False;True,False | [False, False, False] | ['2025-11-17', 97.0, '2026-01-20', 60.5] | 97 | Sep 2025:13/11/2025,Jun 2025:13/08/2025,Mar 2025:30/05/2025 | Aarey Drugs & Pharmaceuticals Limited | -4.1 | 27.1 | Jun 2025:NA | 0.57 | 1.02 | 1.37 | 0.47 | 0.72 | 1.6 | 1.24 | 2.15 | -44.1 | -20.8 | 0.2 | 0.36 | 0.48 | 0.17 | 0.25 | 0.57 | 0.44 | 0.77 | -44.4 | -20 | 1.42 | 1.67 | 96.43 | 84.16 | 102.21 | 108.1 | 133.79 | 105.14 | 126.91 | 210.35 | 14.6 | -27.9 | 9.76 | -1.57 | 3.14 | 1.67 | -3.89 | 1.64 | 3.54 | 0.93 | -0.68 | -150 | -195.7 | Dec 2025 | 2.96 | 6.38 | 0.34 | -0.35 | 53.9 | 2.73 | 0 | -5.74 | -3.56 | 81.48 | 23.54 | Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1, and 3 dioxalane and uracile, as well as active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, including aromatic chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals. In addition, the company trades in industrial solvents and chemicals.The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India. **Website:** [https://www.aareydrugs.com](https://www.aareydrugs.com) | 39.06 | 57.09 | 3.86 | 0 | 44.8 | 1.13 | 0 | 1.24 | 226.74 | 17.87 | 0.58 | ||||||||
| 1 | 99 | 71 | 99 | 08/07/2022 | Medical-Diversified | 1328 | -7.9 | -10.6 | -5.6 | 61.7 | 49.1 | 89.3 | 16.5 | 119.4 | DAILY | 2150.2 | 1483.38 | 1585.38 | 1945.34 | 2306.41 | 1637.1 | 2022.32 | 2249.95 | 2257.48 | 2304.68 | 1.5 | False | False | 0.17 | NA | False | False | False | 244 | Healthcare | 27.3 | False | False | False | False | False | False | 9.8 | False | 20 | 2.04 | 1.2 | 1.4 | 0.9 | False | 6547.35 | 7466.12 | 5038.36 | 7089.01 | 7418.06 | False | 39.3 | 93.95 | 98.44 | 98.86 | 0 | 7.7 | 5.9 | 6 | 6.6 | 72 | 72 | 23.9 | 03/02/2026 | 0.5 | True,True;True,True;False,False | [False, False, True] | ['2026-02-05', 2575.0, '2025-12-19', 1271.0] | 1803.5 | Sep 2025:12/11/2025,Jun 2025:01/08/2025,Mar 2025:22/05/2025 | NGL Fine-Chem Limited | 19.2 | 42.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=712d368f-13c1-4845-9bb1-06cf94c49700.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a96cc0e-f86f-40c8-8395-cc9a5d9fab6e.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/fd0d771b-117a-49cd-951b-b382a258243d.pdf | 14.74 | 7.9 | 7.64 | -0.52 | 0.78 | 9.81 | 9.22 | 12.32 | 86.6 | 1789.7 | 23.86 | 12.79 | 14.96 | 0.87 | 1.26 | 15.88 | 14.92 | 19.94 | 86.6 | 1793.7 | 29.35 | 62.35 | 126.33 | 116.84 | 100.86 | 93.02 | 86.83 | 93.48 | 90.75 | 99.76 | 8.1 | 45.5 | 18.75 | 15.9 | 11.69 | 7.75 | 4.2 | 4.1 | 12.37 | 10.3 | 15.86 | 36 | 287.8 | Dec 2025 | 6.68 | 8.29 | 0.3 | 10.41 | 44.6 | 0 | 0 | 0 | -1.5 | 22.53 | 35.48 | NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, fenbendazole, and xylazine hydrochloride. It also offers human health pharmaceutical ingredients comprising of nitazoxanide and atovaquone; and intermediates and specialty chemicals consisting of trimethyl, triazacylononane, and ethyl glucamine. In addition, the company provides finished dosage forms comprising of diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India. **Website:** [https://www.nglfinechem.com](https://www.nglfinechem.com) | 72.74 | 27.26 | 0 | 0 | 72.74 | 0 | 0 | 4.52 | 1405.32 | 24.09 | 3.22 | ||||||||
| 2 | 99 | 98 | 94 | 20/12/2006 | Medical-Diversified | 1195 | -3.6 | 26.9 | 21.2 | 14.1 | 97.4 | 208 | 5.3 | 221.8 | DAILY | 894.45 | 582.04 | 619.23 | 751.87 | 749.85 | 605.87 | 745.8 | 769.47 | 770.87 | 802.11 | 3.7 | False | False | 0.78 | NA | True | False | False | 61 | Healthcare | 58.2 | False | False | False | False | True | 12/03/2026 | True | 6.7 | False | 5 | 1.71 | 1.8 | 1.4 | 2.7 | False | 45797.3 | 34412.54 | 56785.32 | 49215.32 | 60402.97 | False | 25 | 98.88 | 99 | 99 | 0 | 8.1 | 6.1 | 5.6 | 5.7 | 66.4 | 66.4 | 5.3 | 29/01/2026 | 0.8 | True,True;True,True;True,True | [True, False, False] | ['2026-03-13', 944.8, '2025-11-13', 534.0] | 833.4 | Sep 2025:10/11/2025,Jun 2025:01/08/2025,Mar 2025:26/05/2025 | Venus Remedies Limited | 14.5 | 20.9 | Jun 2025:NA | 25.58 | 20.13 | 9.6 | 21 | 19.6 | 3.51 | 1.22 | 10.51 | 27.1 | 30.5 | 19.14 | 15.06 | 7.18 | 15.71 | 14.66 | 2.63 | 0.91 | 7.86 | 27.1 | 30.6 | 33.9 | 21.31 | 180.26 | 192.75 | 137.18 | 194.97 | 176.52 | 170.1 | 108.61 | 195.16 | -6.5 | 2.1 | 13.79 | 20.81 | 16.06 | 11.21 | 14.87 | 10.21 | 4.45 | 10.37 | 9.98 | 29.6 | 103.8 | Dec 2025 | 7.16 | 11.06 | 0.02 | 16 | 15.7 | 0.39 | 0.28 | 0 | -5.89 | 11.68 | 14.31 | Venus Remedies Limited engages in the pharmaceutical business in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones, immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, solvent, respiratory, and anticoagulant. It is also involved in the provision of portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India. **Website:** [https://www.venusremedies.com](https://www.venusremedies.com) | 41.76 | 54.95 | 2.25 | 1.03 | 41.76 | 1.86 | 0.75 | 2.01 | 1167.4 | 9.17 | 1.66 | |||||||
| 3 | 96 | 96 | 97 | 21/08/2015 | Medical-Diversified | 13 | 2.4 | -0.4 | 8.3 | 25.7 | 36.1 | 32.7 | 15.1 | 75.3 | DAILY | 16.9 | 13.07 | 13.42 | 14.69 | 17.1 | 13.95 | 15.24 | 16.31 | 16.36 | 16.63 | 0.1 | False | False | 0.8 | NA | False | False | False | 131.2 | Healthcare | 98.8 | False | False | True | 20/02/2026 | True | True | 20/02/2026 | True | 4.8 | False | 5 | 0.07 | 0.1 | 0 | 0 | False | 40618.05 | 20336.16 | 60303.54 | 23443.2 | 23041.34 | False | 88.2 | 87.51 | 95.48 | 96.11 | 0 | 4.6 | 4.6 | 3.6 | 4.2 | 48.8 | 48.8 | 31.9 | 14/02/2026 | 2.5 | True,True;True,False;False,False | [False, False, False] | ['2026-02-20', 19.9, '2025-11-17', 11.0] | 16.31 | Sep 2025:14/11/2025,Jun 2025:14/08/2025,Mar 2025:26/05/2025 | ORTIN GLOBAL LIMITED | 8.3 | 27.5 | Jun 2025:NA | ['WEEKLY', '2026-03-09', '2026-03-02'] | -0.05 | -0.5 | -0.18 | -0.16 | -0.11 | -0.47 | -0.1 | -4.14 | 90 | 54.5 | -0.06 | -0.61 | -0.22 | -0.2 | -0.14 | -0.58 | -0.12 | -5.09 | 90.2 | 57.1 | -1.05 | -9.89 | 0.01 | 0.01 | 0.08 | 0.09 | 0.03 | 0.05 | 0.21 | 0.3 | 0 | -66.7 | -71.99 | -500 | -5000 | -200 | -177.78 | -433.33 | -900 | -47.62 | -1016.67 | 90 | -15.4 | Dec 2025 | -36.25 | -25.11 | 0.72 | -457.89 | -15.5 | 0 | 0 | 0 | NA | -70.42 | 20.6 | Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. It operates through Manufacture and Trading segments. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India. **Website:** [https://www.ortinlabsindia.com](https://www.ortinlabsindia.com) | 1.23 | 97.09 | 1.68 | 0 | 1.23 | 1.68 | 0 | 10.57 | 13.69 | -15.74 | 72.05 | |||||
| 4 | 95 | 97 | 96 | 01/07/2002 | Medical-Diversified | 34067 | -0.5 | 3.4 | 12.2 | 18.4 | 26.3 | 39.8 | 0.9 | 53.1 | DAILY | 2121.8 | 1779.05 | 1805.94 | 1947.94 | 2049.75 | 1818.57 | 1966.05 | 2046.46 | 2050.19 | 2091.36 | 83.4 | False | False | 8.22 | Nifty Pharma,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 114 | Healthcare | 51.2 | False | False | False | False | True | 16/02/2026 | True | 2 | False | 20 | 1.86 | 38.7 | 26.8 | 20.9 | False | 406953.85 | 284314.92 | 242933.26 | 309559.35 | 387204.25 | False | 18.9 | 90.45 | 93.27 | 93.82 | 0 | 2 | 2.4 | 2.4 | 2.3 | 81.6 | 81.6 | 0.9 | 16/01/2026 | -0.1 | True,True;True,True;True,True | [False, False, False] | ['2026-03-12', 2141.0, '2025-11-21', 1720.6] | 1933 | Sep 2025:11/11/2025,Jun 2025:30/07/2025,Mar 2025:14/05/2025 | JB Chemicals & Pharmaceuticals Limited | 11.4 | 12.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65369514-828b-4cb8-a706-9779c0eef3cb.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9c335f8-6bfd-42f9-9fe5-42d6804ef0a1.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/ca617db8-1cc0-4ddc-b545-f22a5147da9a.pdf | [2132.8, 2121.8, '10/03/2026', 'DAILY'] | 197.89 | 207.82 | 202.38 | 145.69 | 162.49 | 174.57 | 176.83 | 126.16 | -4.8 | 21.8 | 12.63 | 13.27 | 12.97 | 9.36 | 10.45 | 11.24 | 11.39 | 8.13 | -4.8 | 20.9 | 42.37 | 35.61 | 1064.72 | 1084.9 | 1093.94 | 949.48 | 963.49 | 1000.62 | 1004.4 | 861.73 | -1.9 | 10.5 | 17.16 | 27.78 | 28.54 | 27.5 | 23.85 | 26.42 | 27.04 | 27.91 | 22.99 | -2.7 | 5.1 | Dec 2025 | 20.12 | 25.79 | 0.01 | 27.01 | 44 | -0.76 | -0.12 | 1.22 | 2.11 | 42 | 39.5 | J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India. **Website:** [https://www.jbpharma.com](https://www.jbpharma.com) | 48.78 | 13.94 | 14.55 | 22.71 | 47.56 | 15.31 | 22.83 | 8.73 | 33978.26 | 28.42 | 8.1 | ||||||
| 5 | 95 | 85 | 83 | 19/12/2016 | Medical-Diversified | 54169 | -4.1 | -2.2 | -0.7 | -0.1 | 12.1 | 74.8 | 12.1 | 93.8 | DAILY | 1003.4 | 912.54 | 969.43 | 1030.48 | 1036.12 | 913.01 | 1024.19 | 1031.2 | 1031.51 | 1033.46 | 151.8 | False | False | 39.15 | Nifty Pharma,Nifty Healthcare,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 92.9 | Healthcare | 72.5 | False | False | False | False | False | False | 6.6 | True | No Band | 2.1 | 60.7 | 74.7 | 74.5 | False | 1458678.55 | 1810273.12 | 1970201.82 | 1713063.21 | 1674257.68 | False | 28.8 | 96.24 | 95.55 | 95.36 | 3.1 | 4.2 | 3.6 | 3.1 | 3.4 | 83.2 | 83.2 | 12.1 | 23/01/2026 | -0.9 | True,True;True,True;True,True | [False, False, False] | ['2026-01-07', 1141.0, '2026-02-02', 918.0] | 1128.5 | Sep 2025:23/10/2025,Jun 2025:25/07/2025,Mar 2025:24/04/2025 | Laurus Labs Limited | -1.3 | 8.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=724ecf4e-219c-4603-840f-8cdcd8936daa.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7e3fd55b-03fd-49b5-9b0b-664609c37d92.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/b8dd00f6-ba6a-437c-b95c-dc648f332cbd.pdf | 251.88 | 194.49 | 161.68 | 232.77 | 92.94 | 19.95 | 12.68 | 75.02 | 29.5 | 171 | 4.66 | 3.61 | 3.02 | 4.33 | 1.71 | 0.37 | 0.23 | 1.4 | 29.1 | 172.5 | 6.64 | 2.98 | 1778.29 | 1653.47 | 1569.57 | 1720.3 | 1415.05 | 1223.7 | 1194.91 | 1439.67 | 7.5 | 25.7 | 14.42 | 27 | 24.39 | 24.35 | 24.45 | 20.15 | 14.57 | 14.33 | 16.77 | 10.7 | 34 | Dec 2025 | 7.45 | 9.15 | 0.46 | 25.09 | 64.2 | 0.35 | 0.7 | -0.1 | -2.36 | 53.83 | 37.91 | Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India. **Website:** [https://www.lauruslabs.com](https://www.lauruslabs.com) | 27.49 | 33.57 | 26.52 | 12.42 | 27.59 | 26.17 | 11.72 | 11.27 | 56366.8 | 31.53 | 8.39 | ||||||||
| 7 | 90 | 62 | 97 | 17/12/2015 | Medical-Diversified | 1208 | -2.3 | -2.2 | -7.8 | 24.6 | 9 | 14.5 | 10.9 | 37.1 | DAILY | 603.25 | 536.95 | 529.73 | 536.6 | 622.27 | 548.58 | 562.01 | 600.94 | 602.7 | 616.01 | 5.1 | False | False | 1.01 | NA | False | False | False | 128.9 | Healthcare | 50.2 | False | False | False | False | True | 12/02/2026 | True | 4.6 | False | 10 | 0.82 | 3.2 | 2.9 | 1.9 | False | 79858.4 | 73295.36 | 67953.36 | 73289.8 | 70173.15 | False | 46.7 | 78.83 | 85.94 | 88.3 | 1.1 | 3.7 | 3.6 | 4.1 | 4.8 | 24 | 24 | 38.4 | 12/02/2026 | 0 | True,True;False,False;False,False | [False, False, False] | ['2026-02-13', 677.0, '2026-01-28', 440.0] | 615.8 | Sep 2025:13/11/2025,Jun 2025:07/08/2025,Mar 2025:22/05/2025 | Lincoln Pharmaceuticals Limited | -2 | 9.9 | Jun 2025:NA,Sep 2025:https://www.lincolnpharma.com/Investor/Disclosures%20under%20Regulation%2046%20of%20the%20LODR/17.%20Investor%20Presentation/2025-26/Q2-2025-26.pdf?_t=1763356769 | 28.6 | 19.98 | 27.68 | 11.58 | 20.77 | 26.33 | 23.67 | 18.6 | 43.1 | 37.7 | 14.28 | 9.98 | 13.82 | 5.78 | 10.37 | 13.15 | 11.82 | 9.29 | 43.1 | 37.7 | 41.11 | 46.58 | 166.32 | 163.36 | 154.07 | 168.18 | 146.55 | 161.21 | 147.28 | 142.49 | 1.8 | 13.5 | 10.03 | 14.18 | 15.57 | 15.45 | 15.89 | 16.15 | 17.6 | 15.43 | 12.9 | -8.9 | -12.2 | Dec 2025 | 12.82 | 17.28 | 0 | 15.27 | 13.8 | -0.03 | 0 | 0 | 2.44 | 10.56 | 12.1 | Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. The company was incorporated in 1979 and is based in Ahmedabad, India. **Website:** [https://www.lincolnpharma.com](https://www.lincolnpharma.com) | 49.78 | 45.51 | 4.7 | 0.01 | 49.78 | 4.73 | 0.01 | 1.69 | 1185.87 | 9.1 | 1.82 | |||||||
| 8 | 88 | 98 | 89 | 01/01/1996 | Medical-Diversified | 17120 | -5.9 | -6.3 | 16 | 5.6 | 12.3 | 22.4 | 9.7 | 31.5 | DAILY | 955.85 | 887.7 | 872.4 | 893.33 | 949.86 | 910.88 | 915.22 | 955.16 | 957.64 | 986.48 | 291.4 | False | False | 9.05 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 149.3 | Healthcare | 50.5 | False | False | True | 16/02/2026 | True | True | 16/02/2026 | True | 6.8 | False | 20 | 0.27 | 289 | 148.8 | 151.8 | False | 3130348.15 | 1611038.86 | 1398803.54 | 1894020.27 | 2008332.05 | False | 1.5 | 76.24 | 85.09 | 86.78 | 1.1 | 3.9 | 4 | 4.1 | 3.7 | 44 | 44 | 41.7 | 12/02/2026 | 0.4 | True,False;True,False;False,False | [False, False, False] | ['2026-03-11', 1053.0, '2025-11-17', 805.6] | 949.25 | Sep 2025:14/11/2025,Jun 2025:12/08/2025,Mar 2025:28/05/2025 | Natco Pharma Limited | 13.8 | 25.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c755548f-c325-46ba-8d7a-8c2108a36a18.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c5fe60cd-6aa5-4ff4-9fd3-1e93a3014e6e.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/236bc8c2-778b-4af2-a104-b4e902651e29.pdf | 151.3 | 517.9 | 480.3 | 406 | 132.4 | 676.5 | 668.5 | 386.3 | -70.8 | 14.3 | 8.46 | 28.94 | 26.84 | 22.7 | 7.43 | 37.81 | 37.32 | 21.57 | -70.8 | 13.9 | 105.26 | 77.51 | 647.3 | 1363 | 1328.9 | 1221 | 474.8 | 1371.1 | 1362.6 | 1068.3 | -52.5 | 36.3 | 18.26 | 24.52 | 42.49 | 42.97 | 44.89 | 8.17 | 58.66 | 59.06 | 46.55 | -42.3 | 200.1 | Dec 2025 | 28 | 32.78 | 0.03 | 40.72 | 11 | 1.07 | -0.48 | 0 | 0.08 | 28.25 | 17.75 | NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. **Website:** [https://www.natcopharma.co.in](https://www.natcopharma.co.in) | 49.48 | 29.97 | 15.16 | 5.39 | 49.48 | 14.09 | 5.87 | 1.98 | 14689.03 | 6.85 | 3.22 | ||||||
| 9 | 84 | 86 | 81 | 20/06/2005 | Medical-Diversified | 13642 | -4.2 | -2.6 | 0 | -1.6 | 5.4 | 19.5 | 10.3 | 33.2 | DAILY | 562.2 | 539.14 | 553.33 | 580.27 | 579.09 | 551.96 | 576.75 | 577.36 | 577.31 | 576.23 | 35.2 | False | False | 15.04 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 65 | Healthcare | 62 | False | False | False | False | False | False | 5.1 | False | 20 | 0.71 | 22.6 | 29.6 | 34 | False | 605410.75 | 794552.28 | 1149636.26 | 779395.68 | 631626.26 | False | 49.3 | 83.65 | 85.31 | 84.93 | 4.5 | 3.6 | 3 | 2.9 | 2.9 | 79.2 | 79.2 | 22 | 23/01/2026 | -0.3 | True,True;True,True;False,True | [False, False, False] | ['2026-01-07', 627.0, '2025-11-25', 529.8] | 619.2 | Sep 2025:13/11/2025,Jun 2025:12/08/2025,Mar 2025:28/05/2025 | Granules India Limited | -0.5 | 7.4 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5bc56a95-f04d-4778-9ee4-6496eefbb38a.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7836c830-a1a7-4426-b8e0-edf09ec7ddc0.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/db50795f-3cf6-4abe-a1ef-dab8d469fbc9.pdf | 150.21 | 130.61 | 112.64 | 152.03 | 117.6 | 97.23 | 134.65 | 129.65 | 15 | 27.7 | 6.19 | 5.38 | 4.64 | 6.27 | 4.85 | 4.01 | 5.56 | 5.35 | 15.1 | 27.6 | 20.68 | 16.72 | 1387.94 | 1296.98 | 1210.1 | 1197.43 | 1137.7 | 966.62 | 1179.86 | 1175.78 | 7 | 22 | 11.52 | 22.2 | 21.45 | 20.39 | 21.08 | 20.24 | 21.03 | 21.97 | 21.75 | 3.5 | 9.7 | Dec 2025 | 13.86 | 15.14 | 0.45 | 21.31 | 25 | -0.3 | 0.6 | -0.8 | 5.08 | 22.71 | 19.18 | Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. In addition, the company provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. Granules India Limited was founded in 1984 and is based in Hyderabad, India. **Website:** [https://www.granulesindia.com](https://www.granulesindia.com) | 38.02 | 29.68 | 13.79 | 18.51 | 38.82 | 14.09 | 17.91 | 3.43 | 14834.26 | 13.5 | 2.91 | ||||||||
| 10 | 81 | 84 | 76 | 23/12/2015 | Medical-Diversified | 64033 | -1.6 | -3.2 | -0.9 | -4.8 | -2.6 | 13.8 | 9.7 | 16.1 | DAILY | 5355.5 | 5388.89 | 5544.74 | 5635.61 | 5505.4 | 5466.35 | 5586.73 | 5539.96 | 5536.95 | 5498.91 | 73.6 | False | False | 5.83 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 89.4 | Healthcare | 48.8 | False | False | False | False | True | 13/02/2026 | False | 2.5 | True | No Band | 0.77 | 54.5 | 49.2 | 49.2 | False | 134080.8 | 121439.06 | 139525.94 | 118510.27 | 113636.17 | False | 36.2 | 79.21 | 80.7 | 80.56 | 2.4 | 2.4 | 2.4 | 2.6 | 2.5 | 77.6 | 77.6 | 16.8 | NA | -0.4 | True,False;True,False;True,False | [False, False, False] | ['2026-01-13', 5933.5, '2026-02-20', 5328.5] | 5890 | Sep 2025:13/11/2025,Jun 2025:12/08/2025,Mar 2025:29/05/2025 | Alkem Laboratories Limited | -6.5 | 3.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1f8c5cb-6cae-4760-a9b6-7a66c0c675f3.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6491c139-e5e1-45cd-b7d3-06397d76eafe.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/535e4722-853b-4f09-832f-7a5b3c2be1b2.pdf | 653.03 | 779.11 | 667.91 | 322.39 | 640.79 | 701.96 | 550.24 | 304.48 | -16.2 | 1.9 | 53.19 | 63.99 | 55.56 | 25.58 | 52.34 | 57.6 | 45.6 | 24.55 | -16.9 | 1.6 | 181.11 | 150.19 | 3736.82 | 4000.99 | 3371.14 | 3143.75 | 3374.28 | 3414.67 | 3031.82 | 2935.82 | -6.6 | 10.7 | 9.21 | 22.16 | 23.01 | 21.92 | 12.45 | 22.51 | 22.05 | 20.08 | 13.69 | -3.7 | -1.6 | Dec 2025 | 19.39 | 20.38 | 0.18 | 20.2 | 27 | 0.5 | -0.39 | 0 | 2.87 | 25.17 | 29.05 | Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India. **Website:** [https://www.alkemlabs.com](https://www.alkemlabs.com) | 51.2 | 17.3 | 9.97 | 21.54 | 51.2 | 9.47 | 21.93 | 4.8 | 64796.32 | 19.01 | 4.55 | |||||||
| 11 | 81 | 90 | 85 | 01/01/1996 | Medical-Diversified | 107860 | -2 | -0.9 | 1.9 | 0.9 | -0.7 | 16.6 | 6.3 | 26.7 | DAILY | 1292.3 | 1263.8 | 1256.42 | 1252.07 | 1296.32 | 1255.32 | 1271.05 | 1291.86 | 1292.98 | 1303.8 | 205.6 | False | False | 61.23 | Nifty Pharma,Nifty Healthcare,Nifty Manufacturing,Nifty 100,Nifty 50,Nifty 500 | False | False | False | 97.7 | Healthcare | 73.4 | False | False | False | False | False | False | 3 | True | No Band | 1 | 154.9 | 163.7 | 164.5 | False | 1581855.9 | 1674654.12 | 1722084.08 | 1641068.5 | 1705486.14 | False | 26.1 | 80.38 | 82.76 | 82.47 | 5.8 | 2.4 | 2.7 | 2.3 | 2.3 | 55.2 | 55.2 | 9.1 | 21/01/2026 | -0.7 | True,True;True,False;True,False | [False, False, False] | ['2026-03-12', 1337.3, '2026-01-21', 1148.4] | 1289.4 | Sep 2025:24/10/2025,Jun 2025:23/07/2025,Mar 2025:09/05/2025 | Dr. Reddy's Laboratories Limited | 11.7 | 15.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6446fe27-f8da-4cd3-b147-d176e57c340f.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45e836ba-e747-490e-b57b-d4562e283952.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/ef2cbf94-0330-4ecd-a526-e5efc3b673b3.pdf | [1314.8, '20/10/2025', 'WEEKLY'][1314.8, '01/06/2025', 'MONTHLY'] | 1189.6 | 1336.8 | 1409.9 | 1586.7 | 1404.2 | 1341.9 | 1392.4 | 1309.8 | -11 | -15.3 | 14.5 | 16.14 | 16.99 | 19.09 | 16.94 | 15.05 | 16.69 | 15.7 | -10.2 | -14.4 | 67.77 | 66.87 | 8753.4 | 8828.3 | 8572.1 | 8528.4 | 8381.2 | 8038.2 | 7696.1 | 7113.8 | -0.8 | 4.4 | 13.26 | 21.56 | 22.77 | 25.36 | 23.43 | 27.12 | 25.83 | 27.68 | 25.74 | -5.3 | -20.5 | Dec 2025 | 17.96 | 22.69 | 0.16 | 23.27 | 19.4 | -2.35 | 2.45 | 0 | 0.51 | 22.28 | 20.11 | Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. **Website:** [https://www.drreddys.com](https://www.drreddys.com) | 26.64 | 20.33 | 22.34 | 30.44 | 26.64 | 24.69 | 27.99 | 2.99 | 111688.96 | 11.77 | 3.22 | |||||||
| 12 | 81 | 57 | 87 | 10/03/2016 | Medical-Diversified | 8616 | 0.6 | -2.7 | -8.8 | 2.5 | 2.5 | 2.5 | 17.8 | 4.9 | DAILY | 197.3 | NA | NA | NA | 209.21 | NA | NA | 204.62 | 204.46 | 200.6 | 14.9 | False | False | 16.85 | NA | False | False | False | NA | Healthcare | 38.6 | False | False | False | False | False | False | 4.3 | False | 20 | 1.35 | 15 | NA | NA | False | 715931.7 | NA | NA | NA | 777965.54 | False | NA | 81.74 | 81.21 | 80.82 | 2.4 | 3.8 | 4.5 | 4.3 | 4.4 | 0 | 0 | 17.8 | 05/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2026-02-26', 240.0, '2026-01-14', 188.0] | 216.55 | Sep 2025:14/11/2025,Jun 2025:08/08/2025,Mar 2025:20/05/2025 | Sequent Scientific Limited | -5.6 | 14.9 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0d6e338-4de1-429c-aac2-a94682a694ed.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=faecb00c-1f79-4dd2-a81d-d3fb6336fbae.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/aa67a964-c0c4-457c-9c54-532ec458ca4b.pdf | 48.52 | 72.9 | 17.57 | 10.38 | 41.94 | 6.34 | 9.06 | 1.27 | -33.4 | 15.7 | 0.88 | 2.18 | 0.57 | 0.37 | 1.78 | 0.1 | 0.26 | -0.04 | -59.6 | -50.6 | 0.87 | -1.44 | 858.41 | 850.3 | 441.42 | 401.7 | 774.03 | 368.65 | 390.21 | 361.2 | 1 | 10.9 | 5.64 | 20.46 | 20.37 | 11.82 | 11.51 | 12.89 | 10.61 | 10.75 | 8.93 | 0.4 | 58.7 | Dec 2025 | 3.21 | 8.47 | 0.61 | 17.53 | 49.2 | -2.74 | -5.55 | 9.08 | -3.58 | 56.05 | 69.58 | Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs & Pharmaceuticals Ltd. and changed its name to Sequent Scientific Limited in October 2009. The company was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments. **Website:** [https://www.sequent.in](https://www.sequent.in) | 61.41 | 27.97 | 3.16 | 7.36 | 52.33 | 5.9 | 12.91 | 10.64 | 9049.82 | 19.08 | 3.55 | ||||||||
| 13 | 71 | 78 | 72 | 18/08/2017 | Medical-Diversified | 379 | -0.6 | -0.7 | -3.5 | -6.4 | -3.6 | -3.6 | 18.5 | 14.9 | DAILY | 1254.2 | NA | NA | 1268.63 | 1279.46 | NA | 1276.26 | 1272.88 | 1272.91 | 1271.59 | 0.1 | False | False | 0.09 | NA | False | False | False | NA | Healthcare | 28.2 | False | False | False | False | False | False | 3.4 | False | 5 | 0.84 | 0.1 | 0.1 | NA | False | 719 | 701.68 | NA | 995.45 | 787.86 | False | NA | 73.47 | 72.66 | 70.85 | 6.5 | 3.6 | 3.7 | 3.4 | 3.6 | 31.2 | 31.2 | 18.5 | 11/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-11-21', 1539.0, '2026-01-30', 1091.1] | 1437.9 | Sep 2025:10/11/2025,Jun 2025:11/08/2025,Mar 2025:29/05/2025 | SMS Lifesciences India Limited | -1.3 | 5.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93c18c6b-9e5e-4fc3-80d3-1a7accc00f8d.pdf | 6.65 | 6.42 | 4.39 | 3.48 | 4.86 | 3.3 | 7.1 | 6.47 | 3.6 | 36.8 | 21.9 | 20.18 | 13.76 | 9.82 | 18.09 | 15.45 | 23.15 | 19.52 | 8.5 | 21.1 | 66.52 | 30.07 | 94.78 | 81.37 | 82.5 | 89.11 | 84.6 | 78.46 | 92.55 | 89.99 | 16.5 | 12 | 5.74 | 14.82 | 16.69 | 14.19 | 8.33 | 15.07 | 10.92 | 17.59 | 12.62 | -11.2 | -1.7 | Dec 2025 | 10.76 | 11.78 | 0.34 | 13.45 | 19.1 | 0 | 0.26 | 0.39 | 2.33 | 14.32 | 17.06 | SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic. It is also developing APIs in the areas of anti depressant, anti psychotic, anti hypertension, veterinary, antiviral, and anticoagulant. In addition, the company offers intermediates in the anti ulcer, anti migraine, anti hypertension, erectile dysfunction, anti cancer, antifungal, anti obesity, anti emetic, anti depressant, anti worm, anti gout, anti infective, anti convulsant, antiviral, and anesthesia. It also exports its products. SMS Lifesciences India Limited was founded in 1990 and is based in Hyderabad, India. **Website:** [https://www.smslife.in](https://www.smslife.in) | 71.8 | 27.91 | 0 | 0.29 | 71.41 | 0 | 0.03 | 1.84 | 447.39 | 8.82 | 1.29 | ||||||||
| 14 | 70 | 10 | 7 | 10/05/2017 | Medical-Diversified | 3800 | -4.2 | -6.4 | -20.3 | -33.5 | -25.3 | 43.1 | 35.5 | 49.2 | DAILY | 1121.8 | 1343.85 | 1429.03 | 1316.61 | 1252.09 | 1295.92 | 1312.98 | 1234.73 | 1231.24 | 1189.66 | 4.4 | False | False | 1.67 | NA | False | False | False | 68.7 | Healthcare | 49.4 | False | False | False | False | False | False | 4.9 | False | 20 | 0.7 | 2.1 | 3.1 | 3.4 | False | 35292.5 | 52707.78 | 68007.07 | 48082.43 | 36534.71 | False | 24.1 | 85.35 | 75.41 | 71.85 | 27.1 | 4.1 | 3.9 | 3.8 | 3.8 | 55.2 | 55.2 | 35.5 | 04/02/2026 | -0.7 | True,False;True,False;True,False | [False, False, False] | ['2025-11-21', 1740.0, '2026-03-13', 1116.0] | 1687 | Sep 2025:17/10/2025,Jun 2025:08/08/2025,Mar 2025:29/05/2025 | Zota Health Care LImited | -15.5 | 7.6 | Jun 2025:https://nsearchives.nseindia.com/corporate/ZOTA_08082025192352_InvestorPresentation08082025.pdf,Sep 2025:https://nsearchives.nseindia.com/corporate/ZOTA_19102025170436_InvestorPPT19102025.pdf,Dec 2025:https://nsearchives.nseindia.com/corporate/ZOTA_05022026114424_InvestorPPT05022026.pdf | -29.64 | -16.19 | -13.78 | -12.89 | -18.94 | -12.18 | -12.72 | -6.92 | -83.1 | -56.5 | -8.73 | -5.2 | -4.81 | -4.5 | -6.78 | -4.41 | -4.79 | -2.68 | -67.9 | -28.8 | -19.7 | -5.55 | 142.95 | 128.95 | 103.58 | 97.27 | 72.12 | 67.28 | 56.3 | 49.64 | 10.9 | 98.2 | 25.23 | -0.31 | 4.9 | 3.81 | 2.54 | -8.43 | -1.29 | -2.24 | -3 | -106.3 | 96.3 | Dec 2025 | -35.96 | -16.98 | 0.57 | 2.6 | -48.2 | 4.6 | 2.27 | -5.17 | NA | -32.12 | 203.31 | Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, wellness, over-the-counter products, ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, heart disease, and thyroid disorders. It operates its retail stores under the DAVAINDIA name. The company also exports its products. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India. **Website:** [https://www.zotahealthcare.com](https://www.zotahealthcare.com) | 50.64 | 34.06 | 8.09 | 7.22 | 55.81 | 3.49 | 4.95 | 12 | 3975.93 | 226.81 | 8.41 | ||||||||
| 15 | 69 | 71 | 68 | 01/07/2002 | Medical-Diversified | 21002 | -2.4 | -3.5 | -5.8 | -7.9 | -6.7 | 9.5 | 21.4 | 16.7 | DAILY | 8401 | 8965.64 | 8887.65 | 8614.58 | 8786.42 | 8669.49 | 8739.98 | 8715.46 | 8714.32 | 8671.63 | 4.2 | False | False | 0.62 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 19.2 | Healthcare | 25 | False | False | False | False | False | False | 3.3 | False | 20 | 1.44 | 2.5 | 4.9 | 5.1 | False | 4828.05 | 9374 | 21445.74 | 7797.98 | 5711.07 | False | 67.2 | 80.83 | 76.81 | 74.51 | 22.2 | 2.6 | 2.5 | 2.3 | 2.2 | 48.8 | 48.8 | 21.4 | 11/02/2026 | -0.4 | True,False;True,False;False,False | [False, False, False] | ['2025-11-18', 9469.5, '2026-01-12', 8020.0] | 9282 | Sep 2025:07/11/2025,Jun 2025:14/08/2025,Mar 2025:30/05/2025 | AstraZeneca Pharma India Limited | -7.4 | 1.7 | Jun 2025:NA | 32.59 | 54.22 | 55.83 | 58.25 | 30.85 | 38.43 | -11.79 | 39.48 | -39.9 | 5.6 | 13.04 | 21.69 | 22.33 | 23.3 | 12.34 | 15.37 | -4.72 | 15.79 | -39.9 | 5.7 | 46.3 | 64.6 | 611.57 | 559.09 | 526.31 | 480.48 | 440.29 | 408 | 387.52 | 383.2 | 9.4 | 38.9 | 15.59 | 7.33 | 13.45 | 15.41 | 17.98 | 17.49 | 12.88 | 9.82 | 12.89 | -45.5 | -58.1 | Dec 2025 | 23.63 | 33.4 | 0.04 | 13.2 | 104.5 | -0.03 | 0.29 | 0 | 2.34 | 161.06 | 104.73 | AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. **Website:** [https://www.astrazeneca.in](https://www.astrazeneca.in) | 75 | 16.73 | 2.71 | 5.55 | 75 | 2.74 | 5.26 | 26.29 | 20662.14 | 63.35 | 9.49 | ||||||||
| 16 | 69 | 60 | 69 | 01/07/2002 | Medical-Diversified | 21149 | -1.5 | -4.7 | -8.2 | -7.9 | -10.5 | 13.7 | 22.9 | 24.9 | DAILY | 4623 | 5171.06 | 5042.89 | 4833.62 | 4933.23 | 4982.77 | 4881.99 | 4850.4 | 4848.11 | 4789.69 | 7.4 | False | False | 1.65 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 101.4 | Healthcare | 36.1 | False | False | False | False | False | False | 2.1 | False | 20 | 1.05 | 7.3 | 16.9 | 14.2 | False | 15072.7 | 34602.9 | 36110.77 | 33203.51 | 27007.89 | False | 35.2 | 71.41 | 72.05 | 70.96 | 10.4 | 2.6 | 2.4 | 2.4 | 2.8 | 28 | 28 | 28.3 | 09/02/2026 | -0.2 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 5339.0, '2026-02-02', 4460.0] | 5100.7 | Sep 2025:12/11/2025,Jun 2025:13/08/2025,Mar 2025:19/05/2025 | Pfizer Limited | -3 | 10.3 | Jun 2025:NA | 141.84 | 189.02 | 191.75 | 330.94 | 127.6 | 158.35 | 150.71 | 178.86 | -25 | 11.2 | 31 | 41.32 | 41.91 | 72.34 | 27.89 | 34.61 | 32.94 | 39.1 | -25 | 11.2 | 167.79 | 120.52 | 645.03 | 642.34 | 603.05 | 591.91 | 537.99 | 588.59 | 562.86 | 546.63 | 0.4 | 19.9 | 1.18 | 35.38 | 35.8 | 34.83 | 38.43 | 27.14 | 32.15 | 31.53 | 34.65 | -1.2 | 30.4 | Dec 2025 | 16.4 | 21.62 | 0.01 | 36.08 | 24.8 | 0.11 | -0.06 | 0 | 17.57 | 37.28 | 35.4 | Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India. **Website:** [https://www.pfizerltd.co.in](https://www.pfizerltd.co.in) | 63.92 | 16.32 | 2.71 | 17.05 | 63.92 | 2.6 | 17.11 | 5.5 | 18477.1 | 16.99 | 7.44 | ||||||||
| 17 | 66 | 90 | 78 | 12/08/2002 | Medical-Diversified | 57289 | 1 | -1.3 | 1.9 | -3.3 | -12.8 | -8.9 | 27.1 | 3.7 | DAILY | 26960 | 30155.5 | 29181.5 | 27286.1 | 26753 | 28968.69 | 27338.38 | 26963.7 | 26958.52 | 26969.81 | 22 | False | False | 0.53 | Nifty Pharma,Nifty Healthcare,Nifty MNC,Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 90.2 | Healthcare | 25 | False | False | False | False | True | 04/03/2026 | True | 3.6 | False | 20 | 0.89 | 17.3 | 15.4 | 16.5 | False | 8168.85 | 7275.36 | 8641.87 | 8090.24 | 8691.88 | False | 41.4 | 66.23 | 64.44 | 63.4 | 12 | 2.5 | 2.3 | 2.1 | 2.1 | 3.2 | 3.2 | 27.1 | NA | -1 | False,False;False,False;False,False | [False, False, False] | ['2025-11-25', 30655.0, '2026-03-02', 26000.0] | NA | NA | Abbott India Limited | NA | NA | Jun 2025:NA | [27200.0, 26430.0, '10/03/2026', 'DAILY'] | ['WEEKLY', '2026-03-09', '2026-03-02'] | 375.96 | 415.27 | 365.86 | 367.04 | 360.78 | 358.61 | 328.01 | 287.06 | -9.5 | 4.2 | 176.93 | 195.43 | 172.18 | 172.73 | 169.78 | 168.76 | 154.36 | 135.09 | -9.5 | 4.2 | 665.64 | 565.3 | 1724.04 | 1757.15 | 1738.35 | 1604.59 | 1614.28 | 1632.67 | 1557.61 | 1438.63 | -1.9 | 6.8 | 9.38 | 26.88 | 28.58 | 25.63 | 26.71 | 27.01 | 26.89 | 25.1 | 22.91 | -5.9 | -0.5 | Dec 2025 | 35.68 | 46.25 | 0.05 | 26.96 | 37.6 | 0.03 | -0.11 | 0 | 1.79 | 38.09 | 48.83 | Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited. **Website:** [https://www.abbott.co.in](https://www.abbott.co.in) | 74.99 | 15.83 | 0.19 | 9 | 74.99 | 0.16 | 9.11 | 14.28 | 56171.32 | 26.39 | 8.23 | |||||
| 18 | 65 | 93 | 86 | 29/12/2023 | Medical-Diversified | 4083 | -0.1 | 4.9 | 5.1 | 1.3 | -16.8 | -8.5 | 30.1 | 14.7 | DAILY | 713.55 | 797.27 | 769.28 | 690.52 | 679.94 | 764.31 | 695.08 | 687.32 | 687.39 | 692.25 | 1.9 | True | False | 2.81 | NA | False | False | False | 195.6 | Healthcare | 49.1 | False | False | False | False | False | False | 4 | False | 20 | 1.24 | 1.9 | 6.7 | 4.5 | False | 28074.15 | 101565.64 | 136713.02 | 63157.08 | 35997.85 | False | 85 | 60.33 | 59.03 | 62.79 | 17.5 | 4.3 | 4.2 | 3.9 | 3.6 | 4.8 | 4.8 | 43.4 | 23/01/2026 | -0.6 | False,False;False,False;False,False | [False, False, False] | ['2025-12-09', 776.9, '2026-03-02', 622.0] | 767.5 | Sep 2025:07/11/2025,Jun 2025:07/08/2025,Mar 2025:19/05/2025 | Innova Captab Limited | 5.2 | 12.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c66b086a-c46f-487a-b24f-ed6d0ed7ca4e.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eaef5947-5c69-4eed-a719-ccb22537ab76.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/d6f565b2-98cf-4c22-947e-9f5749103294.pdf | [736.5, '08/01/2026', 'DAILY'] | 42.15 | 29.67 | 31.02 | 29.57 | 34.2 | 35 | 29.48 | 28.72 | 42.1 | 23.2 | 7.37 | 5.18 | 5.42 | 5.17 | 5.98 | 6.12 | 5.15 | 5.02 | 42.3 | 23.2 | 22.41 | 16.49 | 450.29 | 380.38 | 351.54 | 314.74 | 316.46 | 318.2 | 294.27 | 262.63 | 18.4 | 42.3 | 27.21 | 15.41 | 13.64 | 14.82 | 15.15 | 14.71 | 15.63 | 14.33 | 14.5 | 13 | 4.8 | Dec 2025 | 14.34 | 14.63 | 0.33 | 14.77 | 30.8 | 0.02 | 0.07 | 0 | 1.18 | 24.2 | 37.6 | Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through its network of distributors and pharmacies, as well as online through various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India. **Website:** [https://innovacaptab.com](https://innovacaptab.com) | 50.9 | 28.76 | 0.1 | 20.24 | 50.9 | 0.08 | 20.17 | 4 | 4362.17 | 18.58 | 2.91 | |||||||
| 19 | 59 | 67 | 73 | 01/07/2002 | Medical-Diversified | 41069 | -3.2 | -3.7 | -6.6 | -6 | -12 | -8.8 | 31 | 9.2 | DAILY | 2424.3 | 2757.78 | 2597.16 | 2478.48 | 2554.84 | 2614.31 | 2516.26 | 2520.28 | 2520.09 | 2502.68 | 13.3 | False | False | 4.24 | Nifty 500,Nifty Midcap 150,Nifty Midsmallcap 400 | False | False | False | 57.9 | Healthcare | 25 | False | False | False | False | False | False | 4.1 | False | 20 | 0.98 | 10.8 | 14 | 16.6 | False | 52235.7 | 67575.38 | 105538.21 | 68483.95 | 57080.92 | False | 57.4 | 68.55 | 66.32 | 62.78 | 27.7 | 3.3 | 2.6 | 2.5 | 2.7 | 14.4 | 14.4 | 31 | 09/02/2026 | -0.2 | False,False;False,False;False,False | [False, False, False] | ['2026-02-11', 2719.8, '2026-01-21', 2220.3] | 2622.1 | Sep 2025:06/11/2025,Jun 2025:01/08/2025,Mar 2025:13/05/2025 | GlaxoSmithKline Pharmaceuticals Limited | -3.7 | 8.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11959022-3697-4e9d-9517-932286dd43f6.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59ebf753-033f-40f4-ac54-fa8b6e063f12.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/bc215724-313f-4123-9a0e-1583944b869b.pdf | 295.62 | 257.49 | 205.01 | 262.87 | 229.88 | 252.5 | 182.33 | 194.48 | 14.8 | 28.6 | 17.45 | 15.2 | 12.1 | 15.52 | 13.57 | 14.91 | 10.76 | 11.48 | 14.8 | 28.6 | 54.75 | 34.83 | 1041.26 | 979.94 | 805.17 | 974.37 | 949.42 | 1010.77 | 814.65 | 929.8 | 6.3 | 9.7 | 3.06 | 35.66 | 34.26 | 31.2 | 34.2 | 30.75 | 31.83 | 28.3 | 27.67 | 4.1 | 16 | Dec 2025 | 46.87 | 63.25 | 0.02 | 33.98 | 40.2 | -0.16 | -0.05 | 0 | -2.08 | 34.73 | 54.11 | GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India. **Website:** [https://india-pharma.gsk.com](https://india-pharma.gsk.com) | 75 | 12.67 | 4.63 | 7.7 | 75 | 4.79 | 7.75 | 24.05 | 40361.09 | 28 | 10.62 | ||||||||
| 20 | 59 | 73 | 70 | 29/09/2010 | Medical-Diversified | 542 | -5.2 | -3 | -5 | -7.3 | -12.9 | -1.3 | 37.9 | 3.6 | DAILY | 310.6 | 376.2 | 354.51 | 331.67 | 320.22 | 354.43 | 330.64 | 322.82 | 322.5 | 319.19 | 0.4 | False | False | 0.63 | NA | False | False | False | 67.3 | Healthcare | 36.2 | False | False | False | False | False | False | 6.4 | False | 20 | 1.34 | 0.3 | 0.4 | 0.7 | False | 12299.1 | 17325.1 | 22761.5 | 17704.21 | 14599.24 | False | 31.5 | 60.08 | 56.39 | 56.27 | 18.1 | 4.1 | 3.5 | 3.7 | 4.4 | 13.6 | 13.6 | 37.9 | 11/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2026-02-05', 406.0, '2026-03-13', 306.6] | 369 | Sep 2025:13/11/2025,Jun 2025:13/08/2025,Mar 2025:19/05/2025 | Kilitch Drugs (India) Limited | -15.1 | 5 | Jun 2025:NA | 4.31 | 8.04 | 2.27 | 10.22 | 5.61 | 8.61 | 0.11 | 3.68 | -46.4 | -23.2 | 2.53 | 4.69 | 1.73 | 5.94 | 3.41 | 4.93 | 0.77 | 2.05 | -46.1 | -25.8 | 15.26 | 8.34 | 53.81 | 48.92 | 43.14 | 61.23 | 56.17 | 47.47 | 33.45 | 44.82 | 10 | -4.2 | 30.06 | 11.43 | 10.3 | 7.56 | 23.83 | 15.54 | 12.85 | 4.96 | 15.8 | 11 | -26.4 | Dec 2025 | 12.61 | 15.67 | 0.31 | 14.02 | 20.9 | 0 | 0 | 0 | 0.38 | 30.69 | 35.98 | Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India. **Website:** [https://www.kilitch.com](https://www.kilitch.com) | 63.77 | 36.23 | 0 | 0 | 63.77 | 0 | 0 | 2.04 | 590 | 14.22 | 2.85 | ||||||||
| 21 | 59 | 59 | 55 | 30/05/2019 | Medical-Diversified | 109 | -0.3 | -3.8 | -8.5 | -12.7 | -16.2 | -9.3 | 27.6 | 9.4 | DAILY | 88.62 | 98.81 | 98.46 | 94.02 | 94.26 | 106.73 | 94.32 | 92.8 | 92.71 | 91.24 | 0.1 | False | False | 0.33 | NA | False | False | False | 62.5 | Healthcare | 26.6 | False | False | False | False | False | False | 3.4 | False | 20 | 0.8 | 0.2 | 0.2 | 0.3 | False | 8092.05 | 8306.6 | 20503.33 | 10681.26 | 7987.15 | False | 80.1 | 38.46 | 54.19 | 59.66 | 15.7 | 3.8 | 4.2 | 4 | 4.2 | 33.6 | 33.6 | 74.6 | 10/02/2026 | 2.5 | False,False;False,False;False,False | [False, False, False] | ['2025-12-19', 114.0, '2026-01-21', 82.8] | 110.81 | Sep 2025:13/11/2025,Jun 2025:07/08/2025,Mar 2025:08/05/2025 | Par Drugs And Chemicals Limited | -8.3 | 8.7 | Jun 2025:NA | ['DAILY', '2026-03-13', '2026-03-12'] | 4.8 | 4.13 | 3.33 | 1.65 | 0.58 | 8.6 | 2.53 | 3.72 | 16.2 | 727.6 | 3.9 | 3.36 | 2.71 | 1.34 | 0.47 | 6.99 | 2.06 | 3.02 | 16.1 | 729.8 | 10.86 | 11.78 | 29.34 | 28.66 | 26.05 | 22.33 | 21.38 | 34.66 | 22.61 | 22.82 | 2.4 | 37.2 | 12.57 | 20.62 | 21.14 | 13.67 | 10.88 | 6.69 | 32.92 | 18.75 | 26.73 | -2.5 | 208.2 | Dec 2025 | 13.62 | 18.35 | 0 | 17.01 | 7.8 | 0 | 0 | 0.04 | 0.72 | 5.68 | 19.13 | Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, PARSIL-HT, PAR ADD OP, MagSil OF, FlowSil, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It exports its products to Germany, the United Kingdom, Bangladesh, Iran, the United Arab Emirates, Indonesia, Japan, South Korea, and internationally. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India. **Website:** [https://www.pardrugs.com](https://www.pardrugs.com) | 73.41 | 26.59 | 0 | 0 | 73.37 | 0 | 0 | 1.02 | 75.18 | 3.34 | 0.71 | |||||||
| 22 | 55 | 75 | 78 | 03/12/2009 | Medical-Diversified | 6117 | -5.9 | -6.1 | -4.3 | -3.4 | -24.1 | -0.5 | 56 | 20.5 | DAILY | 312.8 | 378.81 | 355.21 | 311.48 | 328.62 | 351.24 | 322.62 | 325.51 | 325.81 | 327.93 | 11.9 | False | False | 11.71 | NA | False | False | False | 142.4 | Healthcare | 59.9 | False | False | False | False | False | False | 7 | False | 20 | 1.02 | 8.5 | 12 | 8.9 | False | 360154.4 | 509946 | 427649.6 | 473508.85 | 470862.48 | False | 47.2 | 56.99 | 53.91 | 54.16 | 24.3 | 4.8 | 4 | 3.7 | 4.6 | 22.4 | 22.4 | 56 | 06/02/2026 | 0.5 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 415.0, '2026-01-27', 259.5] | 390.5 | Sep 2025:13/11/2025,Jun 2025:13/08/2025,Mar 2025:26/05/2025 | Shilpa Medicare Limited | -1 | 11.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd699d43-b02c-49b7-a8ba-9fad8f28b415.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a03c30ef-9c94-4dc3-bb28-276237ee82e1.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/0f646961-62a0-4a72-b502-e3540ce604b9.pdf | 44.58 | 44.07 | 46.89 | 14.51 | 31.78 | 17.95 | 14.06 | 24.5 | 1.2 | 40.3 | 2.28 | 2.25 | 2.4 | 0.74 | 1.62 | 0.92 | 0.72 | 2.82 | 1.3 | 40.7 | 4 | 1.84 | 409.73 | 369.97 | 321.46 | 330.8 | 319.3 | 343.8 | 292.51 | 291.69 | 10.7 | 28.3 | 7.12 | 27.81 | 29.24 | 28.28 | 23.2 | 25.26 | 24.9 | 23.93 | 23.97 | -4.9 | 10.1 | Dec 2025 | 4.21 | 7.82 | 0.24 | 27.22 | 40.8 | 0.05 | 0.67 | -4.09 | 2.15 | 34.3 | 88.34 | Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company provides intermediates; high-purity multi-cyclic and long-chain peptides; specialty and biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India. **Website:** [https://www.vbshilpa.com](https://www.vbshilpa.com) | 40.13 | 40.56 | 10.97 | 8.34 | 44.22 | 10.92 | 7.67 | 2.51 | 6673.48 | 16.33 | 4.66 | ||||||||
| 23 | 55 | 75 | 38 | 15/06/2021 | Medical-Diversified | 56 | -2.2 | -3.3 | -4.5 | -18.2 | -15.8 | -13.6 | 41.2 | 10.9 | DAILY | 29.39 | 35.35 | 36.72 | 32.19 | 30.81 | 36.65 | 32.53 | 30.79 | 30.74 | 30.24 | 0.4 | False | False | 1.68 | NA | False | False | False | 165.3 | Healthcare | 87.5 | False | False | False | False | False | False | 5.7 | False | 20 | 0.94 | 0.8 | 0.7 | 0.6 | False | 140258.2 | 107976.48 | 87256.48 | 119603.05 | 144415.7 | False | 0 | 38.6 | 40.41 | 40.83 | 1.8 | 7.2 | 6.8 | 6.1 | 5.7 | 45.6 | 45.6 | 76.3 | 14/02/2026 | 3 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 46.0, '2026-03-09', 28.0] | 45.65 | Sep 2025:08/11/2025,Jun 2025:22/07/2025,Mar 2025:12/05/2025 | Vineet Laboratories Limited | -4.5 | 8.9 | Jun 2025:NA | 0.85 | 0.4 | -0.87 | -10.53 | -5.71 | -1.83 | -2.13 | 1.92 | 112.5 | 114.9 | 0.44 | 0.21 | -0.45 | -11.42 | -2.97 | -0.95 | -2.31 | 2.08 | 109.5 | 114.8 | -10.52 | 0.54 | 15.65 | 17.42 | 7.44 | 14.08 | 18.1 | 18.96 | 23.86 | 37.05 | -10.2 | -13.5 | NA | 15.85 | 18.25 | 4.17 | -78.41 | -22.82 | -1.64 | -3.31 | 9.23 | -13.2 | 169.5 | Dec 2025 | -89.47 | -27.95 | 3.01 | -9.29 | -5.6 | 0 | 0 | -3.43 | NA | 16.7 | 67.31 | Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was founded in 2007 and is based in Hyderabad, India. **Website:** [https://vineetlabs.co.in](https://vineetlabs.co.in) | 12.46 | 94.02 | 0 | 0 | 15.89 | 0 | 0 | 3.97 | 98.83 | -27.38 | 1.81 | ||||||||
| 24 | 55 | 81 | 67 | 01/01/1970 | Medical-Diversified | 9656 | -3.8 | -4.9 | -2.3 | -8.7 | -20.6 | -14 | 28.9 | 5.5 | DAILY | 4192.9 | 4771.68 | 4655.59 | 4259.46 | 4263.39 | 4620.2 | 4321.75 | 4301.08 | 4303.09 | 4335.25 | 37 | False | False | 0.66 | NA | False | False | False | 259.4 | Healthcare | 28.7 | True | 26/02/2026 | True | True | 26/02/2026 | True | True | 26/02/2026 | True | 4 | False | 20 | 0.1 | 39.9 | 17 | 9.7 | False | 81946.3 | 34754.02 | 21817.44 | 45770.2 | 62447.49 | False | 22.1 | 59.7 | 58.38 | 56.43 | 16.7 | 3.6 | 4.8 | 4.2 | 3.9 | 13.6 | 13.6 | 28.9 | 25/02/2026 | -1.1 | False,False;False,False;False,False | [False, False, False] | ['2025-11-14', 5078.0, '2026-02-24', 3975.0] | 4831.9 | Sep 2025:12/11/2025,Jun 2025:04/08/2025,Mar 2025:02/05/2025 | Sanofi Consumer Healthcare India Limited | 4.6 | 20 | Jun 2025:NA | 66.5 | 62.9 | 60.7 | 50 | 44.3 | 45 | 29 | 62.7 | 5.7 | 50.1 | 28.87 | 27.31 | 26.36 | 21.71 | 19.24 | 19.54 | 12.59 | NA | 5.7 | 50.1 | 104.25 | NA | 251 | 233.9 | 220.9 | 172.6 | 170.7 | 159.9 | 172.3 | 221.6 | 7.3 | 47 | NA | 35.78 | 36.34 | 31.78 | 37.08 | 36.38 | 39.46 | 36.91 | 36.91 | -1.5 | -1.6 | Dec 2025 | 113.29 | 152.07 | 0.06 | 35.18 | 40.2 | -0.11 | 0.12 | 0 | NA | 36.31 | 55.58 | Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Sanofi India Limited. **Website:** [https://www.sanofi.com/en/Consumer-Healthcare/health-and-well-being](https://www.sanofi.com/en/Consumer-Healthcare/health-and-well-being) | 71.27 | 8.57 | 2.83 | 17.33 | 71.27 | 2.94 | 17.21 | 25.15 | 9314.87 | 28.45 | 10.6 | |||||
| 25 | 53 | 66 | 18 | 13/10/2008 | Medical-Diversified | 15590 | -3.4 | -6.8 | -6.9 | -26.1 | -22.5 | 9.8 | 38.5 | 16.8 | DAILY | 12152 | 14328.45 | 14854.16 | 13488.2 | 13010.1 | 14056.46 | 13564.16 | 12956.17 | 12935.93 | 12712.61 | 62.6 | False | False | 0.86 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 72.5 | Healthcare | 67.4 | False | False | False | False | True | 23/02/2026 | True | 4.9 | False | 20 | 1.05 | 22.4 | 21.1 | 25.2 | False | 47481.85 | 45262.32 | 58139.37 | 48135.64 | 42915.12 | False | 23 | 69.64 | 60.33 | 57.93 | 40.4 | 3.4 | 3.5 | 3.8 | 4.3 | 47.2 | 47.2 | 38.5 | 09/02/2026 | 0.5 | True,False;True,False;False,False | [False, False, False] | ['2025-11-14', 17950.0, '2026-03-13', 12013.0] | 18113 | Sep 2025:07/11/2025,Jun 2025:31/07/2025,Mar 2025:15/05/2025 | Neuland Laboratories Limited | -12.5 | 2 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f91a6323-fca2-455a-809c-f3f2e7095ed2.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f4a2a49-c8a4-4d3b-92d1-0149798a4093.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/f789c6ae-40ed-49ab-8264-dc74f0976e23.pdf | 40.57 | 96.85 | 13.9 | 27.81 | 101.59 | 32.84 | 97.87 | 67.56 | -58.1 | -60.1 | 31.62 | 75.49 | 10.83 | 21.68 | 79.18 | 25.6 | 76.28 | 52.66 | -58.1 | -60.1 | 202.74 | 233.89 | 439.71 | 514.27 | 292.75 | 328.36 | 398.03 | 310.84 | 439.6 | 385.01 | -14.5 | 10.5 | 14.13 | 17.54 | 30.25 | 11.78 | 15.56 | 21.76 | 20.02 | 28.06 | 27.77 | -42 | -19.4 | Dec 2025 | 14.83 | 18.66 | 0.16 | 20.21 | 87 | 0.3 | 1.17 | -0.01 | 1.84 | 96.08 | 29.09 | Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. **Website:** [https://www.neulandlabs.com](https://www.neulandlabs.com) | 32.63 | 31.76 | 20.9 | 14.72 | 32.64 | 20.6 | 13.55 | 9.62 | 15806.04 | 46.03 | 10.04 | |||||||
| 26 | 52 | 93 | 67 | 01/07/2002 | Medical-Diversified | 1225 | -3.5 | 5.5 | 4.8 | -8.4 | -26.8 | -10.7 | 39.3 | 18 | DAILY | 182.96 | 215.38 | 206.75 | 175.3 | 173.72 | 202.19 | 179.1 | 175.33 | 175.37 | 177.3 | 5.2 | False | False | 2.18 | NA | False | False | False | 91.7 | Healthcare | 32.6 | False | False | False | False | True | 12/03/2026 | True | 6.1 | False | 20 | 2.28 | 3 | 1.5 | 1.1 | False | 285094.6 | 147823.8 | 175440.01 | 227531.98 | 430456.68 | False | 49.9 | 56.43 | 49.62 | 50.24 | 38.1 | 7.9 | 5 | 4.4 | 4.3 | 4.8 | 4.8 | 44.2 | 21/01/2026 | 1.2 | False,False;False,False;False,False | [False, False, False] | ['2025-12-03', 222.0, '2026-01-22', 155.0] | 226.48 | Sep 2025:03/11/2025,Jun 2025:26/07/2025,Mar 2025:06/05/2025 | Jagsonpal Pharmaceuticals Limited | 11.3 | 22.5 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a28bb2c3-a0a4-47c5-80f0-ce2bf8f80577.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b7e04c3-b648-49bd-89ca-4a911cbf1b42.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/981ce57f-34e9-402c-a674-be68d8abf0a3.pdf | ['DAILY', '2026-03-13', '2026-03-12'] | 10.95 | 12.57 | 10.8 | 6.58 | 31.99 | 11.46 | 5.33 | 3.55 | -12.9 | -65.8 | 1.64 | 1.89 | 1.62 | 0.99 | 4.82 | 1.73 | 0.81 | 0.54 | -13.2 | -66 | 8.34 | 3.4 | 72.95 | 74.47 | 75.61 | 58.56 | 74.03 | 74.69 | 61.44 | 43.49 | -2 | -1.5 | 11.13 | 22.3 | 22.08 | 18.78 | 14.87 | 21.4 | 21.81 | 16.68 | 6.14 | 1 | 4.2 | Dec 2025 | 18.58 | 22.95 | 0.03 | 19.75 | 29.8 | 0 | 0.07 | -0.15 | 0.98 | 27.89 | 36.22 | Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India. **Website:** [https://www.jagsonpal.com](https://www.jagsonpal.com) | 67.39 | 30.34 | 2.12 | 0.15 | 67.54 | 2.12 | 0.08 | 4.83 | 1073.51 | 15.97 | 3.81 | ||||||
| 27 | 51 | 68 | 59 | 19/09/2003 | Medical-Diversified | 3173 | -2.4 | -2.6 | -6.4 | -11.5 | -31.6 | 2.2 | 38.3 | 11.5 | DAILY | 347.75 | 449.28 | 438.18 | 376.33 | 363.86 | 424.35 | 377.78 | 362.73 | 362.22 | 356.36 | 3.8 | False | False | 4.1 | NA | False | False | False | 42 | Healthcare | 45 | False | False | False | False | False | False | 3.3 | False | 20 | 0.89 | 5.7 | 6.8 | 9.6 | False | 103878.9 | 123671.72 | 221477.29 | 135459.23 | 119604.4 | False | 49.3 | 46.85 | 44.64 | 45.47 | 15 | 3.3 | 2.5 | 2.3 | 2.7 | 21.6 | 21.6 | 66.1 | 03/02/2026 | -0.4 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 475.8, '2026-03-09', 344.5] | 520.5 | Sep 2025:07/11/2025,Jun 2025:18/07/2025,Mar 2025:06/05/2025 | Aarti Drugs Limited | -11 | 8.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31508af2-3857-41d0-87c6-11cc757f16df.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2f24fc5-1403-4507-8511-5a45fb18ff06.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/5a8d8db7-2785-4ce0-82c9-154468f69abb.pdf | ['DAILY', '2026-03-13', '2026-03-12'] | 40.55 | 45.16 | 53.97 | 62.77 | 37.09 | 34.96 | 33.27 | 47.31 | -10.2 | 9.3 | 4.44 | 4.96 | 5.91 | 6.84 | 4.06 | 3.84 | 3.62 | 5.15 | -10.5 | 9.4 | 18.42 | 18.65 | 601.71 | 652.79 | 590.51 | 676.76 | 556.6 | 598.33 | 555.34 | 619.99 | -7.8 | 8.1 | 5.74 | 9.15 | 12.91 | 12.55 | 13.79 | 11.09 | 11.21 | 11.7 | 13.84 | -29.1 | -17.5 | Dec 2025 | 12.69 | 13.09 | 0.39 | 12.16 | 15.7 | -0.53 | 0.22 | 0.31 | -2.45 | 19.58 | 24.17 | Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India. **Website:** [https://www.aartidrugs.co.in](https://www.aartidrugs.co.in) | 55.03 | 32.71 | 2.15 | 10.12 | 54.72 | 2.68 | 9.9 | 2.16 | 3734.72 | 12.04 | 1.48 | |||||||
| 28 | 50 | 60 | 56 | 19/07/2002 | Medical-Diversified | 7568 | -3.6 | -2.4 | -8.1 | -12.4 | -4.3 | -14.1 | 38.3 | 7.1 | DAILY | 167.01 | 197.02 | 179.52 | 174.8 | 175.05 | 192.4 | 176.12 | 173.88 | 173.78 | 172.12 | 9.3 | False | False | 25.44 | NA | False | False | False | 61.8 | Healthcare | 56.1 | False | False | False | False | False | False | 4.1 | False | 20 | 1.65 | 5.9 | 7.9 | 8.7 | False | 532796.1 | 716183 | 1077483.54 | 693739.58 | 601803.74 | False | 49.6 | 45.9 | 47.87 | 48.89 | 10.7 | 3.3 | 3.2 | 3.2 | 3.6 | 35.2 | 35.2 | 53.4 | 05/02/2026 | -1.4 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 201.3, '2026-01-30', 156.0] | 195.11 | Sep 2025:13/11/2025,Jun 2025:12/08/2025,Mar 2025:19/05/2025 | Marksans Pharma Limited | -7 | 6.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7449f75b-f499-4f5c-a133-db74f1549d81.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=561963c2-f7bd-403c-8ef9-fe5811634512.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/06ee0731-fe61-4466-9013-15e76d05ed7b.pdf | 113.69 | 99.14 | 58.2 | 90.73 | 105.06 | 97.76 | 89.07 | 77.64 | 14.7 | 8.2 | 2.5 | 2.17 | 1.29 | 2 | 2.31 | 2.13 | 1.96 | 1.73 | 15.2 | 8.2 | 8.4 | 6.92 | 754.43 | 720.41 | 619.99 | 708.46 | 681.85 | 641.92 | 590.62 | 560.01 | 4.7 | 10.6 | 18.25 | 21.31 | 20.06 | 16.15 | 17.92 | 20.35 | 22.87 | 21.74 | 19.58 | 6.2 | 4.7 | Dec 2025 | 16.77 | 20.03 | 0.12 | 18.99 | 21 | -8.79 | 0.63 | 0 | 0.77 | 16.7 | 17.2 | Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India. **Website:** [https://marksanspharma.com](https://marksanspharma.com) | 43.87 | 42.08 | 8.13 | 5.91 | 43.87 | 16.92 | 5.28 | 2.82 | 7228.62 | 12.15 | 2.58 | ||||||||
| 29 | 48 | 29 | 32 | 26/05/2022 | Medical-Diversified | 333 | 3.2 | -2.9 | -14.6 | -20.4 | 3.2 | -28.6 | 35.7 | 8 | DAILY | 40.17 | 46.43 | 46.97 | 46.89 | 44.08 | 48.25 | 46.05 | 43.54 | 43.39 | 41.56 | 0.7 | False | False | 3.2 | NA | False | False | False | 70.9 | Healthcare | 38.6 | False | False | False | False | False | False | 9.6 | False | 20 | 2.51 | 0.9 | 1.8 | 1.6 | False | 148051.55 | 295383.4 | 391357.49 | 236372.21 | 182635.66 | False | 67 | 50.71 | 45.64 | 43.4 | 30.4 | 5.6 | 5.4 | 4.7 | 4.5 | 55.2 | 55.2 | 60.1 | 12/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-12-24', 56.9, '2026-03-13', 37.4] | 54.24 | Sep 2025:14/11/2025,Jun 2025:08/08/2025,Mar 2025:08/05/2025 | Medico Remedies Limited | -15.4 | 5.1 | Jun 2025:NA | 2.87 | 2.57 | 1.82 | 4.34 | 2.62 | 1.55 | 1.58 | 3.1 | 11.7 | 9.5 | 0.35 | 0.31 | 0.22 | 0.52 | 0.32 | 0.19 | 0.19 | 0.37 | 12.9 | 9.4 | 1.22 | 1 | 58.68 | 52.64 | 38.25 | 41.3 | 39.49 | 39.35 | 30.8 | 41.32 | 11.5 | 48.6 | 11.23 | 7.38 | 5.19 | 7.37 | 16.13 | 7.88 | 6.12 | 9.16 | 11.25 | 42.2 | -6.3 | Dec 2025 | 17.57 | 21.31 | 0.19 | 8.67 | 28.7 | 0.19 | -0.01 | 0 | 1.03 | 28.69 | 51.27 | Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It exports its products. Medico Remedies Limited was incorporated in 1994 and is based in Mumbai, India. **Website:** [https://medicoremedies.com](https://medicoremedies.com) | 61.38 | 38.13 | 0.49 | 0 | 61.38 | 0.3 | 0.01 | 4.99 | 344.23 | 17.31 | 1.8 | ||||||||
| 30 | 47 | 61 | 71 | 08/05/2006 | Medical-Diversified | 110 | -3.1 | -4.5 | -7.9 | -7 | -20.8 | -15.8 | 46.2 | 5.4 | DAILY | 69.24 | 83.99 | 78.68 | 72.12 | 74.37 | 82.54 | 73.12 | 72.61 | 72.59 | 71.75 | 0.1 | False | False | 0.78 | NA | False | False | False | 36.6 | Healthcare | 49.1 | False | False | False | False | False | False | 4.9 | False | 20 | 0.82 | 0.1 | 0.1 | 0.1 | False | 14309.55 | 10686.6 | 20394.46 | 11721.28 | 12593.91 | False | 71.1 | 34.13 | 41.28 | 45.5 | 5.9 | 5.8 | 5.4 | 5.1 | 5.2 | 10.4 | 10.4 | 58.8 | 11/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 82.9, '2026-01-27', 65.7] | 81.59 | Sep 2025:12/11/2025,Jun 2025:11/08/2025,Mar 2025:29/05/2025 | Bal Pharma Limited | -3.5 | 13.6 | Jun 2025:NA | 1.79 | 0.72 | 0.21 | 5.41 | 0.52 | 1.04 | 0.26 | 5.53 | 148.6 | 244.2 | 1.12 | 0.45 | 0.13 | 3.41 | 0.3 | 0.65 | 0.16 | 3.46 | 148.9 | 273.3 | 4.53 | 4.68 | 87.69 | 74.02 | 65.87 | 81.88 | 73.15 | 73.69 | 74.36 | 94.63 | 18.5 | 19.9 | 12.11 | 10.88 | 7.74 | 9.2 | 9.33 | 10.59 | 10.44 | 8.7 | 10.14 | 40.6 | 2.7 | Dec 2025 | 9.66 | 10.1 | 1.98 | 9.36 | 13.6 | -0.09 | 0 | 0 | 1.03 | 15.46 | 26.05 | Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India. **Website:** [https://www.balpharma.com](https://www.balpharma.com) | 50.86 | 49.01 | 0.14 | 0 | 50.86 | 0.23 | 0 | 1.41 | 255.71 | 7.94 | 0.83 | ||||||||
| 31 | 44 | 74 | 31 | 12/08/2002 | Medical-Diversified | 3110 | -4.3 | 0.5 | -4.7 | -20.6 | -19.8 | -8.6 | 31 | 6.6 | DAILY | 1881 | 2274.12 | 2235.53 | 2053.91 | 1902.06 | 2188.32 | 2021.05 | 1921.09 | 1917.79 | 1896.05 | 1.5 | False | False | 0.45 | NA | False | False | False | 71.7 | Healthcare | 27.1 | False | False | False | False | False | False | 4.6 | False | 20 | 1 | 0.6 | 0.9 | 0.9 | False | 7702.6 | 11367.84 | 15076.53 | 10206.54 | 8998.05 | False | 49.8 | 58.02 | 51.78 | 50.11 | 42.9 | 4.1 | 3.3 | 3 | 3 | 32 | 32 | 36.8 | 27/01/2026 | -1.5 | False,False;False,False;False,False | [False, False, False] | ['2025-12-17', 2392.2, '2026-03-04', 1764.2] | 2462.6 | Sep 2025:17/10/2025,Jun 2025:25/07/2025,Mar 2025:28/04/2025 | RPG Life Sciences Limited | -10.5 | 1.6 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe61fba0-e96e-409d-a10b-8198353f80e5.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71ac5e3d-7c6e-41ce-98ae-80cf42a5113a.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/3249c429-2e6c-4f5d-af4c-2501f62a0704.pdf | 22.13 | 36.85 | 26.29 | 117.35 | 34.93 | 4.2 | 26.76 | 13.24 | -39.9 | -36.6 | 13.38 | 22.28 | 15.9 | 70.95 | 21.12 | 2.54 | 16.18 | 8.01 | -39.9 | -36.6 | 110.79 | 53 | 180.03 | 181.68 | 168.92 | 143.09 | 172.71 | 172.21 | 165.42 | 126.99 | -0.9 | 4.2 | 11.71 | 22.09 | 21.48 | 21 | 17.81 | 28.46 | 26.67 | 23.62 | 16.32 | 2.8 | -22.4 | Dec 2025 | 25.53 | 32.8 | 0 | 20.74 | 15.4 | -0.11 | 0.34 | 0 | 0.94 | 35.15 | 27.5 | RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust. **Website:** [https://www.rpglifesciences.com](https://www.rpglifesciences.com) | 72.95 | 19.01 | 1 | 7.04 | 72.95 | 1.11 | 6.7 | 5.62 | 2970.66 | 18.8 | 4.41 | ||||||||
| 32 | 43 | 69 | 44 | 01/07/2002 | Medical-Diversified | 5744 | -3.8 | -2.6 | -6.2 | -16.1 | -24.4 | -9.7 | 33.1 | 1 | DAILY | 352.85 | 435.42 | 422.07 | 380.86 | 369.71 | 419.94 | 381.48 | 370.5 | 370.15 | 366.62 | 2.6 | False | False | 4.94 | NA | False | False | False | 49.8 | Healthcare | 30.3 | False | False | False | False | False | False | 4.7 | False | 20 | 1.15 | 2.6 | 2.7 | 3.8 | False | 70799.75 | 72329.66 | 135275.98 | 81776.81 | 77219.6 | False | 49.1 | 46.06 | 46.02 | 46.19 | 17.3 | 3.8 | 4.2 | 3.6 | 3.7 | 6.4 | 6.4 | 46.4 | 05/02/2026 | 0.4 | False,False;False,False;False,False | [False, False, False] | ['2025-12-29', 433.5, '2026-03-02', 349.2] | 428 | Sep 2025:05/11/2025,Jun 2025:07/08/2025,Mar 2025:28/05/2025 | FDC Limited | -6.8 | 5.5 | Jun 2025:NA | ['WEEKLY', '2026-03-09', '2026-03-02'] | 28.3 | 28.37 | 121.35 | 38.67 | 37.04 | 72.04 | 119.04 | 46.28 | -0.2 | -23.6 | 1.74 | 1.74 | 7.45 | 2.38 | 2.28 | 4.42 | 7.31 | 2.84 | 0 | -23.7 | 16.39 | 18.75 | 464.71 | 473.03 | 648.41 | 491.89 | 464.11 | 513.85 | 638.27 | 462.03 | -1.8 | 0.1 | 9.46 | 11.25 | 7.15 | 21.65 | 10.97 | 10.05 | 13.65 | 22.97 | 12.19 | 57.3 | 11.9 | Dec 2025 | 11.83 | 15.9 | 0.01 | 13.49 | 26.5 | -0.11 | -0.54 | 0 | 3.52 | 50.7 | 25.55 | FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India. **Website:** [https://www.fdcindia.com](https://www.fdcindia.com) | 69.66 | 21.76 | 2.32 | 6.27 | 69.66 | 2.43 | 6.81 | 2.36 | 5727.45 | 15.34 | 2.76 | |||||||
| 33 | 41 | 63 | 27 | 01/07/2002 | Medical-Diversified | 13448 | 2 | 3.2 | -7.5 | -22.3 | -24.8 | -2.6 | 32.4 | 7.4 | DAILY | 844.2 | 1073.23 | 1042.09 | 941.82 | 860.75 | 1014.28 | 925.49 | 864.74 | 862.24 | 837.51 | 13.1 | False | False | 8.34 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 57.4 | Healthcare | 52.3 | False | False | False | False | False | False | 6.5 | False | 20 | 1.69 | 10.1 | 9.7 | 10.1 | False | 153105.5 | 147033.58 | 216852.02 | 155868.54 | 171618.56 | False | 53.3 | 55.1 | 45.89 | 42.51 | 46.1 | 4.7 | 4 | 3.7 | 3.6 | 23.2 | 23.2 | 35.6 | 06/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-11-17', 1162.0, '2026-03-09', 786.0] | 1181.2 | Sep 2025:31/10/2025,Jun 2025:29/07/2025,Mar 2025:16/05/2025 | Jubilant Pharmova Limited | -10 | 4.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33cbcc25-39e8-416f-94d1-e21b941fa817.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77615ab8-04a3-4a72-9b9e-3d3fe8271bc1.pdf,Dec 2025:https://www.jubilantpharmova.com/Uploads/files/99q2consfileQ3'FY26_Earnings_PPT_vf.pdf | 55.8 | 119.9 | 102.5 | 151.3 | 100.7 | 102.5 | 481.8 | -61.8 | -53.5 | -44.6 | 3.51 | 7.55 | 6.46 | 9.64 | 6.33 | 6.45 | 30.26 | -3.68 | -53.5 | -44.5 | 52.69 | 4.84 | 2122.5 | 1966.4 | 1900.7 | 1928.8 | 1821.7 | 1752.3 | 1731.7 | 1758.6 | 7.9 | 16.5 | 3.9 | 13.63 | 17.36 | 15.23 | 17.9 | 15.76 | 16.51 | 14.52 | 15.43 | -21.5 | -13.5 | Dec 2025 | 9.55 | 9.54 | 0.44 | 15.98 | 31.1 | -0.6 | 0.7 | 0 | 2.83 | 60.13 | 36.42 | Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India. **Website:** [https://www.jubilantpharmova.com](https://www.jubilantpharmova.com) | 47.67 | 24.57 | 15.96 | 11.23 | 47.67 | 16.56 | 10.53 | 2.04 | 15660.75 | 11.87 | 1.98 | ||||||||
| 34 | 39 | 84 | 68 | 01/01/1996 | Medical-Diversified | 2088 | -5.3 | -4.2 | -1.1 | -8.2 | -28.8 | -14.6 | 45.9 | 13.8 | DAILY | 38.11 | 48.92 | 44.35 | 39.12 | 40.83 | 46.94 | 40.29 | 40.29 | 40.31 | 40.21 | 61.5 | False | False | 35.26 | NA | False | False | False | 172.4 | Healthcare | 64.3 | True | 23/02/2026 | True | True | 23/02/2026 | True | True | 23/02/2026 | True | 7.5 | False | 20 | 0.25 | 72.4 | 35 | 21.3 | False | 13764898.45 | 6639549.42 | 5078610.64 | 7759996.27 | 9127150.6 | False | 39.7 | 28.78 | 32.58 | 36.05 | 0 | 4.5 | 5.5 | 4.9 | 5 | 12 | 12 | 77.3 | 10/02/2026 | 0.1 | False,False;False,False;False,False | [False, False, False] | ['2026-02-24', 48.8, '2026-01-27', 33.5] | 46.28 | Sep 2025:14/11/2025,Jun 2025:06/08/2025,Mar 2025:12/05/2025 | Morepen Laboratories Limited | -4.5 | 22.3 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28584864-96e0-424a-9bed-30e2567dafb5.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa06ebc2-ccb2-4517-b132-573e056b37d5.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/864c812f-bdb9-4ed3-b185-3eb8c54bea52.pdf | 27.5 | 41.04 | 11.41 | 20.31 | 26.69 | 34.85 | 36.17 | 28.74 | -33 | 3 | 0.5 | 0.75 | 0.2 | 0.37 | 0.49 | 0.64 | 0.71 | 0.55 | -33.3 | 2 | 2.15 | 1.88 | 484.16 | 411.58 | 425.24 | 465.85 | 452.78 | 437.73 | 455.22 | 423.07 | 17.6 | 6.9 | 16.26 | 9.57 | 7.46 | 5.68 | 9.07 | 7.98 | 10.07 | 11.34 | 11.44 | 28.3 | 19.9 | Dec 2025 | 11.78 | 15.08 | 0.13 | 8.03 | 21.1 | 0 | -0.24 | 0 | 5.37 | 19.06 | 28.56 | Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India. **Website:** [https://www.morepen.com](https://www.morepen.com) | 35.65 | 61.46 | 1.62 | 1.25 | 35.65 | 1.62 | 1.49 | 1.75 | 2204.88 | 13.71 | 1.23 | |||||
| 35 | 36 | 42 | 19 | 27/06/2018 | Medical-Diversified | 1938 | -1.5 | -3.9 | -11.7 | -25.6 | -35 | -7.8 | 39.9 | 0.7 | DAILY | 441.25 | 572.89 | 567.43 | 504.08 | 466.52 | 552.41 | 496.1 | 467.36 | 466.22 | 454.67 | 2.9 | False | False | 2.55 | NA | False | False | False | 51.7 | Healthcare | 58 | False | False | False | False | False | False | 2.7 | False | 20 | 1.32 | 4.2 | 5.3 | 10.7 | False | 61336.85 | 78698.82 | 150284.49 | 99313.94 | 75395.99 | False | 30.6 | 44.75 | 42.99 | 42.65 | 39 | 3.5 | 3.4 | 3.4 | 4.2 | 16.8 | 16.8 | 76.3 | 06/02/2026 | 0.1 | False,False;False,False;False,False | [False, False, False] | ['2025-12-10', 641.0, '2026-03-13', 438.0] | 607.05 | Sep 2025:05/11/2025,Jun 2025:25/07/2025,Mar 2025:15/05/2025 | Solara Active Pharma Sciences Limited | -6.3 | 12.6 | Jun 2025:NA,Sep 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/b27a99c9-58ce-4cba-bff2-6095b3027384.pdf,Dec 2025:https://www.solara.co.in/uploads/2026/2/SE_Press_Release_Solara.pdf | -17.43 | -10.1 | 10.52 | -2.1 | 8.09 | 8.01 | -13.46 | -255.45 | -72.6 | -315.5 | -4.82 | -2.79 | 2.91 | -0.58 | 2.24 | 2.22 | -3.74 | -53.2 | -72.8 | -315.2 | 0.15 | -118.21 | 349 | 313.54 | 319.15 | 273.01 | 300.31 | 346.95 | 363.49 | 299.43 | 11.3 | 16.2 | -0.58 | 10.7 | 11.08 | 17.87 | 16.62 | 19.21 | 17.67 | 11.53 | 3.26 | -3.4 | -44.3 | Dec 2025 | 0.05 | 6.01 | 0.51 | 13.9 | -83.6 | -1.6 | 0.95 | -0.01 | NA | -22.89 | 33.04 | Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antifungal, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India. **Website:** [https://www.solara.co.in](https://www.solara.co.in) | 42 | 42.37 | 11.98 | 3.64 | 42.01 | 13.58 | 2.69 | 1.27 | 2579.36 | 14.18 | 2.06 | ||||||||
| 36 | 34 | 25 | 30 | 01/07/2002 | Medical-Diversified | 2073 | -2.7 | -7.3 | -15.4 | -21.1 | -23.4 | -12.8 | 35.7 | 0.9 | DAILY | 80.75 | 103.4 | 99.4 | 93.93 | 90.06 | 101.11 | 92.91 | 89 | 88.79 | 85.84 | 2.1 | False | False | 7.48 | NA | False | False | False | 49.7 | Healthcare | 29.1 | False | False | False | False | False | False | 4.5 | False | 20 | 1.6 | 2.4 | 2.2 | 2.6 | False | 236348.3 | 218579.98 | 374938.8 | 238304.32 | 253883.18 | False | 63.3 | 39 | 38.79 | 38.09 | 22.2 | 3 | 2.9 | 2.8 | 2.7 | 14.4 | 14.4 | 62.4 | 12/02/2026 | -0.6 | False,False;False,False;False,False | [False, False, False] | ['2025-12-03', 106.4, '2026-03-13', 80.0] | 103.37 | Sep 2025:10/11/2025,Jun 2025:12/08/2025,Mar 2025:13/05/2025 | Alembic Limited | -18.1 | 1 | Jun 2025:NA | 60.13 | 128.49 | 61.64 | 68.45 | 65.39 | 121.02 | 55.82 | 72.15 | -53.2 | -8 | 2.34 | 5 | 2.4 | 2.67 | 2.55 | 4.71 | 2.17 | 2.81 | -53.2 | -8.2 | 12.1 | 10.46 | 74.34 | 55.86 | 49.75 | 60.27 | 57.92 | 52.91 | 50.78 | 49.04 | 33.1 | 28.3 | 24.58 | 36.91 | 41.6 | 39.38 | 45.35 | 45.58 | 37.01 | 40.17 | 49.25 | -11.3 | -19 | Dec 2025 | 13.69 | 6.9 | 0 | 40.63 | 6.5 | -0.09 | 0 | 0 | 0.53 | 8.63 | 9.25 | Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provision of project management and marketing consultancy services; and leasing of commercial properties. It manufactures and markets fermentation and chemistry based on active pharmaceutical ingredient; and engages in research and development. In addition, it is involved in power generation through co-generation plants and wind power sources. The company serves individuals, corporates, business houses, and pharmaceutical companies. The company was founded in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Pvt. Ltd. **Website:** [https://www.alembiclimited.com](https://www.alembiclimited.com) | 70.88 | 27.78 | 1.29 | 0.05 | 70.88 | 1.38 | 0.05 | 0.82 | 2082.17 | 12.15 | 8.67 | ||||||||
| 37 | 32 | 79 | 31 | 14/01/2005 | Medical-Diversified | 1811 | -1.9 | -1 | -3 | -20.7 | -33.1 | -10.3 | 43.9 | 4.4 | DAILY | 196.28 | 264.33 | 251.69 | 210.02 | 199.71 | 249.68 | 211.79 | 201.14 | 200.83 | 197.99 | 1.1 | False | False | 3.79 | NA | False | False | False | 72 | Healthcare | 41.1 | False | False | False | False | False | False | 5 | False | 20 | 0.79 | 1.8 | 2.1 | 1.9 | False | 52699.45 | 60448.4 | 89079.6 | 61607.37 | 57480.68 | False | 42.9 | 32.27 | 32.82 | 33.89 | 28.3 | 5.1 | 3.5 | 3.3 | 3.9 | 12 | 12 | 63 | 03/02/2026 | -0.1 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 271.4, '2026-03-09', 188.1] | 269.25 | Sep 2025:06/11/2025,Jun 2025:24/07/2025,Mar 2025:22/05/2025 | Indoco Remedies Limited | -16.3 | 8.3 | Jun 2025:https://www.indoco.com/mda/mda-jun25.pdf,Sep 2025:https://www.indoco.com/mda/mda-sep25.pdf,Dec 2025:https://www.indoco.com/mda/mda-dec25.pdf | ['DAILY', '2026-03-13', '2026-03-12'] | -29.45 | -9.21 | -36.35 | -41.34 | -28.4 | -10.01 | 1.82 | 22.03 | -219.8 | -3.7 | -3.23 | -0.86 | -3.88 | -4.38 | -2.86 | -1.04 | 0.28 | 2.46 | -275.6 | -12.9 | -7.99 | 10.68 | 445.36 | 484.67 | 439.67 | 390.21 | 410.55 | 432.66 | 431.49 | 449.64 | -8.1 | 8.5 | 8.51 | 7.08 | 8.88 | 3.99 | -0.2 | 2.93 | 9.3 | 11.07 | 10.87 | -20.3 | 141.6 | Dec 2025 | -7.02 | -0.49 | 1.02 | 5.19 | -15.9 | -0.15 | -0.01 | 0 | NA | -15.19 | 28.43 | Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. It offers stomatological, gastrointestinal, respiratory, anti-infectives, vitamins/minerals/nutrients, ophthal/ontological, dermatology, urological, anti-diabetic, gynaecological, lifestyle management, pain/analgesic, and cardiac products. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, as well as anti-haemorrhoidal creas and calcium preparations. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom synthesis of molecules and intermediates, process chemistry research and development, non-infringing process designing and scale up, and analytical method development/validation solutions, as well as contract manufacturing services. The company also exports its products. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India. **Website:** [https://www.indoco.com](https://www.indoco.com) | 58.9 | 21.76 | 1.1 | 18.15 | 58.9 | 1.25 | 18.16 | 1.85 | 2794.84 | 28.9 | 1.59 | |||||||
| 38 | 28 | 34 | 58 | 01/07/2002 | Medical-Diversified | 561 | -4.7 | -5.3 | -13.3 | -11.6 | -33.4 | -27.7 | 45.7 | 0.2 | DAILY | 116.25 | 158 | 149.96 | 135.27 | 127.84 | 156.55 | 133.03 | 127.22 | 126.95 | 123.58 | 2.4 | False | False | 2.68 | NA | False | False | False | 70.4 | Healthcare | 55.6 | False | False | False | False | False | False | 4.9 | False | 20 | 1.83 | 3.7 | 4.2 | 7 | False | 186391.45 | 209753.16 | 318438.98 | 268519.91 | 212087.39 | False | 26.6 | 19.44 | 24.77 | 27.19 | 22.2 | 4.6 | 3.8 | 3.8 | 3.8 | 25.6 | 25.6 | 68.6 | 22/01/2026 | -0.8 | False,False;False,False;False,False | [False, False, False] | ['2025-12-30', 159.9, '2026-03-13', 116.0] | 154.75 | Sep 2025:12/11/2025,Jun 2025:29/07/2025,Mar 2025:15/05/2025 | Kopran Limited | -14.8 | 9 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34a85d3c-5413-4ebe-ba88-0482f9c81fef.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5efeeebf-c74b-4ca5-95ff-e03ddf133bc5.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/3f303848-f87d-40a5-8766-3c3283823b81.pdf | 9.34 | -9.92 | 7.45 | 9.68 | 10.4 | 7.38 | 11.1 | 18.62 | 194.2 | -10.2 | 1.94 | -2.06 | 1.54 | 2.01 | 2.16 | 1.53 | 2.3 | 3.86 | 194.2 | -10.2 | 7.99 | 10.57 | 194.28 | 117.91 | 135.22 | 172.36 | 166.24 | 151.56 | 139.44 | 186.08 | 64.8 | 16.9 | 11.86 | 9.14 | -4.48 | 10.45 | 9.92 | 11.94 | 9.72 | 13.02 | 11.66 | 304 | -23.5 | Dec 2025 | 7.64 | 9.75 | 0.31 | 7.05 | 33.9 | -0.24 | 0 | 0 | -2.38 | 14.98 | 21.9 | Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India. **Website:** [https://www.kopran.com](https://www.kopran.com) | 44.42 | 55.21 | 0.36 | 0 | 44.42 | 0.6 | 0 | 1.12 | 679.91 | 13.7 | 1.1 | ||||||||
| 39 | 26 | 23 | 37 | 19/10/2022 | Medical-Diversified | 18584 | -3.9 | -7.9 | -15.8 | -18.6 | -31.4 | -30.7 | 42 | 0.5 | DAILY | 139.81 | 186.34 | 180.8 | 160.89 | 157.17 | 181.81 | 161.29 | 155 | 154.74 | 151.1 | 42.3 | False | False | 86.59 | Nifty Pharma,Nifty Healthcare,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 76.9 | Healthcare | 65.1 | False | False | False | False | False | False | 4.2 | True | No Band | 1.64 | 45.2 | 53.4 | 52.5 | False | 2716905.3 | 3205209.2 | 3908497.03 | 3056486.89 | 3065283.75 | False | 55 | 29.7 | 24.08 | 24.79 | 50.9 | 4.2 | 3.1 | 3.1 | 3.1 | 19.2 | 19.2 | 54.6 | 28/01/2026 | -2 | False,False;False,False;False,False | [False, False, False] | ['2025-11-14', 198.0, '2026-03-13', 139.1] | 199.33 | Sep 2025:05/11/2025,Mar 2025:14/05/2025 | Piramal Pharma Limited | -9.2 | 10.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03caf78a-1ca0-4ca9-9e2c-4f8eec46ead1.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f67db704-3ad8-48fe-baeb-efaaa2dc2d88.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/94be2676-fca1-4eeb-9e5c-fa84c33674c3.pdf | -136.19 | -99.22 | -81.7 | 153.5 | 3.68 | 22.59 | -88.64 | 101.27 | -37.3 | -3800.8 | -1.02 | -0.75 | -0.61 | 1.16 | 0.03 | 0.17 | -0.67 | 0.77 | -36 | -3500 | 0.69 | 0.13 | 2139.87 | 2043.72 | 1933.71 | 2754.07 | 2204.22 | 2241.75 | 1951.14 | 2552.36 | 4.7 | -2.9 | NA | 9.15 | 7.76 | 5.52 | 20.37 | 15.32 | 15.24 | 10.48 | 20.76 | 17.9 | -40.3 | Dec 2025 | 1.11 | 6.45 | 0.6 | 11.52 | -113.7 | -0.61 | 0.79 | 0 | NA | -34.27 | 551.9 | Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India. **Website:** [https://www.piramalpharma.com](https://www.piramalpharma.com) | 34.86 | 19.35 | 29.66 | 15.68 | 34.86 | 30.27 | 14.89 | 2.3 | 22944.29 | 17.77 | 2.59 | ||||||||
| 40 | 25 | 44 | 30 | 08/01/2010 | Medical-Diversified | 1169 | -2.3 | -5.8 | -11.4 | -21.2 | -29.9 | -25.1 | 40.8 | 1.2 | DAILY | 827.7 | 1122.96 | 1069.45 | 946.93 | 896.39 | 1092.97 | 942.87 | 892.4 | 890.29 | 865.42 | 0.5 | False | False | 0.36 | NA | False | False | False | 87.4 | Healthcare | 25.4 | False | False | False | False | False | False | 4.6 | False | 20 | 0.78 | 0.6 | 0.5 | 0.5 | False | 5372.75 | 5246.64 | 5329.92 | 5186.96 | 5983.95 | False | 54.8 | 23.87 | 23.86 | 23.54 | 13.8 | 3 | 2.8 | 2.5 | 2.3 | 6.4 | 6.4 | 56.3 | 22/01/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 1152.7, '2026-03-13', 818.0] | 1192.6 | Sep 2025:17/10/2025,Jun 2025:04/08/2025,Mar 2025:23/05/2025 | TTK Healthcare Limited | -15.6 | 4.2 | Jun 2025:NA | 10.53 | 20.39 | 13 | 16.15 | 16.73 | 17.2 | 31.58 | 18.27 | -48.4 | -37.1 | 7.45 | 14.43 | 9.2 | 11.43 | 11.84 | 12.17 | 22.35 | 12.93 | -48.4 | -37.1 | 57.79 | 44.47 | 209.3 | 203.57 | 226.43 | 190.36 | 204.74 | 198.49 | 207.9 | 181.06 | 2.8 | 2.2 | 4.42 | 3.41 | 2.62 | 1.18 | 6.3 | 3.75 | 4.15 | 3.32 | 6.86 | 30.2 | -9.1 | Dec 2025 | 6.89 | 9.26 | 0.02 | 3.27 | 19.5 | -0.01 | -0.1 | 0 | 0.76 | 27.78 | 31.79 | TTK Healthcare Limited engages in the animal welfare and human pharma product, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, Human Pharma, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, anti-parasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripewater name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Human Pharma is involved in the development and commercialization of such as gynecology, infertility, respiratory, orthopedics, cardiology, and general health therapeutic needs. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd. **Website:** [https://www.ttkhealthcare.com](https://www.ttkhealthcare.com) | 74.56 | 22.46 | 1.89 | 1.08 | 74.56 | 1.9 | 1.18 | 1.08 | 571.91 | 5.71 | 0.69 | ||||||||
| 41 | 22 | 32 | 34 | 18/11/2022 | Medical-Diversified | 1133 | -2.7 | 0.6 | -13.7 | -19.7 | -32.4 | -22.6 | 48.7 | 4.6 | DAILY | 12.06 | 16.36 | 15.3 | 13.06 | 12.74 | 15.39 | 13.23 | 12.64 | 12.62 | 12.34 | 1.9 | False | False | 46.46 | NA | False | False | False | 89.3 | Healthcare | 49.4 | False | False | False | False | False | False | 3.5 | False | 20 | 1.12 | 2.3 | 2.6 | 2.2 | False | 1477156.25 | 1632932.36 | 1814773.33 | 1530470.76 | 1506401.07 | False | 60.9 | 30.28 | 24.86 | 23.43 | 58.5 | 3.9 | 4.5 | 4.2 | 4.6 | 8 | 8 | 56.8 | 12/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 17.2, '2026-02-24', 11.5] | 16.67 | Sep 2025:12/11/2025,Jun 2025:08/08/2025,Mar 2025:19/05/2025 | Syncom Formulations (India) Limited | -15.4 | 2 | Jun 2025:NA | 18.86 | 16.84 | 15.73 | 17.5 | 12.79 | 10.95 | 7.63 | 6.75 | 12 | 47.5 | 0.2 | 0.18 | 0.17 | 0.19 | 0.14 | 0.12 | 0.08 | 0.07 | 11.1 | 42.9 | 0.52 | 0.25 | 114.59 | 121.44 | 116.55 | 148.46 | 127.03 | 101.49 | 86.83 | 73.27 | -5.6 | -9.8 | 17.51 | 18.48 | 15.42 | 13.54 | 11.77 | 11.49 | 11.75 | 12.07 | 12.02 | 19.8 | 60.8 | Dec 2025 | 15.5 | 18.59 | 0 | 14.6 | 16.5 | 0.16 | 0 | 0 | 0.47 | 15.08 | 38.62 | Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of commodities and renting of properties. It also exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India. **Website:** [https://www.syncomformulations.com](https://www.syncomformulations.com) | 50.57 | 49.17 | 0.26 | 0 | 50.57 | 0.1 | 0 | 3.01 | 1135.53 | 11.73 | 2.27 | ||||||||
| 42 | 13 | 8 | 13 | 22/04/2004 | Medical-Diversified | 2492 | -3.8 | -3.2 | -21.2 | -29.2 | -40.6 | -24.3 | 50.6 | 2.9 | DAILY | 158.95 | 248.65 | 245.32 | 209.04 | 177.23 | 231.96 | 200.16 | 178.25 | 177.3 | 167.81 | 6.3 | False | False | 6.38 | NA | False | False | False | 91.6 | Healthcare | 40.7 | False | False | False | False | False | False | 5.6 | False | 20 | 1.42 | 6.2 | 5 | 4.8 | False | 357883.95 | 288214.18 | 358061.46 | 322298.33 | 372137.54 | False | 61.1 | 29.05 | 16.66 | 14.72 | 76.8 | 5 | 4.8 | 4.6 | 4.5 | 40 | 40 | 59.9 | 03/02/2026 | 0 | False,False;False,False;False,False | [False, False, False] | ['2025-12-17', 274.3, '2026-03-09', 154.5] | 297.6 | Sep 2025:04/11/2025,Jun 2025:12/08/2025,Mar 2025:21/05/2025 | Dishman Carbogen Amcis Limited | -30.6 | 2.1 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=705c5aa8-230e-46c3-937a-2f3d2579f146.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab8f3d09-ba4a-4c81-ae26-67c4fb8c809f.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/55cb3566-6a34-4458-966e-b5fe0a4b893b.pdf | -12.97 | 65.27 | 23.41 | 43.09 | 4.63 | 33.09 | -77.57 | -69.92 | -119.9 | -380.1 | -0.83 | 4.16 | 1.49 | 2.75 | 0.3 | 2.11 | -4.95 | -4.46 | -120 | -376.7 | 0.21 | -9.79 | 719.8 | 652.65 | 708.05 | 716.34 | 682.34 | 789.04 | 523.78 | 654.71 | 10.3 | 5.5 | 5.82 | 15.71 | 22.81 | 19.87 | 21.32 | 20.54 | 18.65 | 5.53 | 9.57 | -31.1 | -23.5 | Dec 2025 | -0.32 | 2.42 | 0.4 | 19.86 | 21 | -0.41 | -0.1 | 0 | NA | -47.88 | 85.53 | Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutical and cosmetic-related products; vitamin D products and its analogues; hand and body wash, sanitizers, and antiseptics; and phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol, lanolin-related products, and liquid and lyophilized sterile injectables. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP. **Website:** [https://imdcal.com](https://imdcal.com) | 59.32 | 31.75 | 7.66 | 1.27 | 59.32 | 8.07 | 1.37 | 0.39 | 4436.97 | 7.36 | 1.59 | ||||||||
| 43 | 13 | 6 | 4 | 01/07/2002 | Medical-Diversified | 2597 | -5.3 | 0.7 | -22.9 | -37.7 | -27.8 | -35.2 | 43 | 4.7 | DAILY | 512.1 | 732.42 | 737.71 | 670.26 | 599.19 | 771.22 | 652.33 | 587.71 | 584.47 | 545.67 | 6.4 | False | False | 1.53 | NA | False | False | False | 85.3 | Healthcare | 30.2 | False | False | False | False | True | 27/02/2026 | False | 7.1 | False | 20 | 0.83 | 10.1 | 7.3 | 8.7 | False | 111814.35 | 80617.9 | 97187.59 | 97245.78 | 123851.09 | False | 27.6 | 12.71 | 11.62 | 10.66 | 27.8 | 5.3 | 5.1 | 4.5 | 4.3 | 30.4 | 30.4 | 80.7 | 11/02/2026 | -0.9 | False,False;False,False;False,False | [False, False, False] | ['2025-11-26', 899.0, '2026-03-09', 489.0] | 871.95 | Sep 2025:11/11/2025,Jun 2025:12/08/2025,Mar 2025:26/05/2025 | Orchid Pharma Limited | -25.8 | 1.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e356cbc-55b6-49b8-8e6b-a336760bb3e6.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d207b0b0-043d-4d16-b3d5-57a929c180cd.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/9a21b328-f927-43c9-83cb-c1112f37bf04.pdf | ['DAILY', '2026-03-13', '2026-03-12'] | -12.61 | -5.72 | 14.91 | 22.29 | 20.78 | 27.24 | 29.35 | 32.96 | -120.5 | -160.7 | -2.49 | -1.13 | 2.94 | 4.39 | 4.1 | 5.37 | 5.79 | 6.5 | -120.4 | -160.7 | 19.65 | 18.17 | 207.27 | 193.52 | 172.93 | 237.48 | 217.34 | 222.7 | 244.41 | 217.1 | 7.1 | -4.6 | 13.76 | 0.75 | -0.76 | 8.2 | 11.79 | 12.13 | 13.62 | 13.29 | 13.32 | 198.7 | -93.8 | Dec 2025 | 8.21 | 8.07 | 0.22 | 5.21 | 137.7 | -0.39 | 0.34 | 0 | 0.4 | -51.42 | 60.12 | Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is based in Narsinghpur, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited. **Website:** [https://www.orchidpharma.com](https://www.orchidpharma.com) | 69.84 | 9.61 | 1.17 | 19.38 | 69.84 | 1.56 | 19.04 | 2.04 | 2744.42 | 37.09 | 3.38 | ||||||
| 44 | 7 | 10 | 10 | 25/11/2021 | Medical-Diversified | 896 | -5.5 | -11.5 | -20.4 | -30.8 | -33.3 | -55.1 | 61.9 | 0.6 | DAILY | 283.95 | 438.8 | 414.25 | 358.18 | 331.92 | 423.55 | 354.77 | 328.13 | 326.94 | 312.36 | 5.2 | False | False | 1.29 | NA | False | False | False | 74.9 | Healthcare | 40.8 | False | False | False | False | False | False | 6.1 | False | 20 | 2.06 | 7.5 | 7.6 | 6.6 | False | 163088.55 | 164051.9 | 210943.18 | 169714.53 | 211680.54 | False | 58.9 | 16.48 | 7.45 | 6.35 | 86.8 | 3.7 | 3.6 | 3.7 | 3.7 | 15.2 | 15.2 | 61.9 | 16/01/2026 | -0.1 | False,False;False,False;False,False | [False, False, False] | ['2025-11-28', 458.0, '2026-03-13', 282.1] | 481 | Sep 2025:17/10/2025,Jun 2025:28/07/2025,Mar 2025:26/05/2025 | Bajaj Healthcare Limited | -27.4 | 7.1 | Jun 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/694c44ba-0d45-4319-af14-704e8dec00ac.pdf,Sep 2025:https://www.bseindia.com/xml-data/corpfiling/AttachHis/9fe05889-e3b6-44f7-b223-81acc576aadb.pdf | 15.67 | 11.11 | 11.83 | 11.18 | 11.72 | 9.46 | 7.13 | -29.92 | 41 | 33.7 | 4.96 | 3.52 | 3.75 | 3.54 | 3.71 | 3 | 2.58 | -10.84 | 40.9 | 33.7 | 12.51 | -30.36 | 161.22 | 147.91 | 148.84 | 154.47 | 122.79 | 133.09 | 132.25 | 133.9 | 9 | 31.3 | 5.76 | 19.03 | 18.22 | 16.47 | 7.62 | 17.62 | 18.43 | 18.53 | 11.97 | 4.4 | 8 | Dec 2025 | 10.69 | 11.44 | 0.49 | 15.33 | 18 | 0.06 | -0.03 | 0 | -0.97 | 14.31 | 18.77 | Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 | 59.19 | 36.67 | 1.18 | 2.96 | 59.19 | 1.12 | 2.99 | 1.84 | 1121.38 | 10.04 | 1.83 | ||||||||
| 45 | 7 | 31 | 11 | 01/07/2002 | Medical-Diversified | 2271 | -3.9 | 0.1 | -14.1 | -30.5 | -35.9 | -49.5 | 55.3 | 4.4 | DAILY | 322.6 | 485.02 | 445.36 | 378.65 | 345.27 | 469.45 | 375.03 | 345.09 | 343.86 | 331.18 | 0.9 | False | False | 2.1 | NA | False | False | False | 74.7 | Healthcare | 29.8 | False | False | False | False | False | False | 5.1 | False | 20 | 1.25 | 1 | 1 | 0.8 | False | 27448.25 | 27553.72 | 34817.16 | 29898.3 | 36164.79 | False | 52.4 | 10.99 | 8.68 | 8.02 | 69.6 | 5.4 | 4.5 | 3.9 | 4.2 | 0.8 | 0.8 | 65.6 | 05/02/2026 | -1.5 | False,False;False,False;False,False | [False, False, False] | ['2025-11-19', 499.4, '2026-03-09', 309.0] | 482.2 | Sep 2025:11/11/2025,Jun 2025:04/08/2025,Mar 2025:22/05/2025 | Unichem Laboratories Limited | -24.9 | 3.6 | Jun 2025:NA | 264.29 | -11.89 | -10.47 | 52.97 | 57.85 | 24.63 | 2.07 | -129.31 | 2322.8 | 356.9 | 37.54 | -1.69 | -1.49 | 7.52 | 8.22 | 3.5 | 0.29 | -18.37 | 2321.3 | 356.7 | 19.53 | -13.32 | 521.17 | 578.96 | 526.6 | 587.18 | 533.09 | 507.36 | 483.34 | 431.7 | -10 | -2.2 | 13.85 | 8.59 | 11.43 | 4.27 | 14.25 | 16.04 | 10.94 | 8.31 | 5.87 | -24.8 | -46.4 | Dec 2025 | 5.59 | 6.24 | 0.21 | 9.81 | 7.7 | 0 | -0.01 | 0 | 0.34 | 2.15 | 63.21 | Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. Unichem Laboratories Limited was founded in 1944 and is based in Mumbai, India. **Website:** [https://www.unichemlabs.com](https://www.unichemlabs.com) | 70.22 | 18.05 | 0.99 | 10.73 | 70.22 | 0.99 | 10.74 | 0.93 | 2571.7 | 9.67 | 1.16 | ||||||||
| 46 | 6 | 6 | 22 | 22/08/2017 | Medical-Diversified | 79 | -3.3 | -9.2 | -23 | -24 | -49.1 | -49.5 | 59.8 | 1.7 | DAILY | 6.12 | 10.36 | 9.66 | 7.89 | 7.16 | 10.07 | 7.72 | 7.04 | 7.01 | 6.62 | 0.1 | False | False | 8.92 | NA | False | False | False | 36.5 | Healthcare | 68.4 | False | False | False | False | False | False | 7.1 | False | 20 | 0.98 | 0.2 | 0.2 | 0.3 | False | 191091.7 | 204922.68 | 402724.83 | 208174.1 | 186768.92 | False | 60.8 | 4.2 | 4.32 | 4.81 | 0 | 6.2 | 6.2 | 5.4 | 4.9 | 2.4 | 2.4 | 75.4 | 13/02/2026 | 2.4 | False,False;False,False;False,False | [False, False, False] | ['2025-11-13', 9.9, '2026-03-13', 6.0] | 9.69 | Sep 2025:14/11/2025,Jun 2025:11/08/2025,Mar 2025:28/05/2025 | Vaishali Pharma Limited | -23 | 2.3 | Jun 2025:NA | 1.3 | 1.18 | 1.28 | -4.29 | 1.44 | 1.97 | 1.7 | -4.68 | 10.2 | -9.7 | 0.1 | 0.09 | 0.12 | -0.4 | 0.13 | 0.18 | 0.16 | -0.44 | 11.1 | -23.1 | 0.08 | 0.07 | 24.65 | 33.45 | 23.75 | 32.25 | 27.91 | 20.79 | 18.08 | 32.4 | -26.3 | -11.7 | 10.51 | 6.33 | 4.16 | 5.77 | -18.73 | 4.87 | 11.64 | 13 | -20.96 | 52.2 | 30 | Dec 2025 | 1.52 | 4.93 | 0.23 | -1.51 | -68 | 0 | 0 | 5.29 | NA | 15.3 | 27.78 | Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, cardiac, anti-diabetic, anti-inflamatory/ananlgesic/anti-pyretic, topical steroids/corticosteroids, anti-fungal, vitamins, and other formulations. In addition, it offers veterinary, nutraceutical, oncology, herbal, and surgical products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India. **Website:** [https://www.vaishalipharma.com](https://www.vaishalipharma.com) | 31.61 | 68.39 | 0 | 0 | 26.32 | 0 | 0 | 1.18 | 94.39 | 51.02 | 0.83 | ||||||||
| 47 | 5 | 12 | 10 | 01/07/2002 | Medical-Diversified | 2125 | -4.3 | -5.1 | -19.3 | -31.1 | -33.5 | -55.1 | 62.3 | 0.7 | DAILY | 172.41 | 261.99 | 231.66 | 199.72 | 193.62 | 253.01 | 200.48 | 189.13 | 188.67 | 182.7 | 14.9 | False | False | 3.84 | NA | False | False | False | 168.6 | Healthcare | 31.1 | False | False | False | False | True | 12/02/2026 | True | 4.1 | False | 20 | 0.39 | 20.9 | 34.4 | 44.8 | False | 730034.25 | 1193907.5 | 1109169.8 | 1331872.3 | 936433.77 | False | 11.6 | 9.51 | 8.42 | 7.66 | 73.7 | 4.2 | 3.6 | 3.8 | 4.4 | 7.2 | 7.2 | 76.8 | 11/02/2026 | -1.2 | False,False;False,False;False,False | [False, False, False] | ['2025-12-04', 261.0, '2026-03-09', 171.2] | 256.15 | Sep 2025:13/11/2025,Jun 2025:07/08/2025,Mar 2025:14/05/2025 | Hikal Limited | -9.6 | 16.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ceadab9-5729-4e46-bf9f-b1da87ff03de.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66ab4388-389a-4085-8f56-600cc6246fe0.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/eee9564c-bde9-4418-b7ea-9b7baee0cf40.pdf | -5.9 | -34.9 | -22.4 | 50.2 | 17.2 | 18.3 | 5.1 | 33.9 | 83.1 | -134.3 | -0.48 | -2.83 | -1.82 | 4.07 | 1.39 | 1.48 | 0.41 | 2.75 | 83 | -134.5 | 7.36 | 5.64 | 494.3 | 318.5 | 380.4 | 552.4 | 447.7 | 452.9 | 406.8 | 514.1 | 55.2 | 10.4 | 4.29 | 16.73 | 2.26 | 6.6 | 22.34 | 16.1 | 16.54 | 14.26 | 18.36 | 640.3 | 3.9 | Dec 2025 | 7.38 | 9.85 | 0.57 | 13.66 | -164.2 | -1.92 | 1.9 | 0 | -4.89 | -89.8 | 48.77 | Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs). Its Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. The company also collaborates with other companies; and offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, it offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India. **Website:** [https://www.hikal.com](https://www.hikal.com) | 68.85 | 21.78 | 2.31 | 7.05 | 68.85 | 4.23 | 5.15 | 1.78 | 2786.89 | 11.39 | 1.6 |
Quarter | EPS | QoQ EPS | YoY EPS | Sales(Cr.) | QoQ Sales | YoY Sales | OPM |
|---|---|---|---|---|---|---|---|
Dec 25 | 0.2 | -44.4 | -20.0 | 96 | 14.6 | -27.9 | -1.57 |
Sep 25 | 0.36 | -25.0 | -36.8 | 84 | -17.7 | -20.0 | 3.14 |
Jun 25 | 0.48 | 182.4 | 9.1 | 102 | -5.4 | -19.5 | 1.67 |
Mar 25 | 0.17 | -32.0 | -77.9 | 108 | -19.2 | -48.6 | -3.89 |
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1, and 3 dioxalane and uracile, as well as active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, including aromatic chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals. In addition, the company trades in industrial solvents and chemicals.The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
Website: https://www.aareydrugs.com
Disclaimer: This stock summary is generated by AI. ChartsMaze does not guarantee its accuracy, completeness, or timeliness. The data may be outdated and may not reflect real-time events or news. Please verify the information independently before making any investment decisions. For more details, check our Terms & Conditions.